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 1 
1 INTRODUCTION 
 
1.1 TNFα – a proinflammatory cytokine 
 
1.1.1 What is TNFα? 
Tumor necrosis factor alpha (TNFα) is a proinflammatory cytokine and the prototypical 
member of the TNF protein superfamily. The polypeptide of approximately 17 kDa is 
produced by a variety of immune cells including T-lymphocytes, B-lymphocytes, natural 
killer cells and macrophages (1). TNFα plays a key regulatory role in several inflammatory 
processes, in host defense against bacterial infection as well in autoimmune disorders (2,3). 
TNFα was given its name as it was first discovered in 1975 with the cytotoxic ability to kill 
mouse fibrosarcoma cells (4). 
 
 
1.1.2 TNF-receptors 
The cellular response to TNFα is mediated through its interaction with two different 
membrane receptors (5-7). These receptor subtypes, namely TNF-receptor 1 (TNF-R1) and 
TNF-receptor 2 (TNF-R2), are of different size and are expressed to different levels in 
different cells (8). While TNF-R1, with its 55 kDa also referred to as p55-receptor, is widely 
expressed, expression of the 75-kDa TNF-R2 (p75-receptor) is mainly found on immune and 
endothelial cells (9). Whereas the extracellular domains of the two receptors are strikingly 
similar in structure, their intracellular domains appear to be unrelated (10). 
 
 
1.1.3 Signaling pathways 
By interacting with its membrane receptors TNFα can activate distinctive signaling pathways 
in the cell (1,6). Since TNF-R1 and TNF-R2 are differentially expressed on cells and tissues 
TNFα can lead to a range of cellular responses and initiate both distinct and overlapping 
signal transduction pathways resulting in either cell death on one side or survival, 
differentiation, proliferation, and migration on the other side. 
Among many intracellular factors involved in TNF-receptor signaling the families of the 
death domain homologues and of the TNF-receptor associated factors (TRAFs) should be 
mentioned (11-13). TRAF-signaling is described upon activation of both TNF-receptor 
subtypes and associated with the activation (TRAF2) or inactivation (TRAF1) of NF-κB and 
consecutive regulation of proinflammatory effects (14-16). TNF-R1 has an intracellular death 
domain, which can interact with the death domains of other cytosolic proteins such as 
TRADD (TNF-receptor associated death domain), FADD (Fas associated death domain) or 
RIP (receptor interacting protein). So, by activation of caspase-8 and other caspases TNFα 
similarly to the cell death signaling receptor Fas (CD95) induces apoptosis (17). Other 
cellular responses described upon activation of TNF-R1 include the activation of kinases such 
as PKC (proteinkinase C), JNK (c-Jun NH2-terminal kinase) and NIK (NF-κB induced 
kinase) and the activation of intracellular lipases (18). PKC is well described to activate 
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NADPH-oxidase in several tissues and therefore leading to the production of reactive oxygen 
species (ROS) causing oxidative stress (19,20). 
Despite multiple variations and modulations in the downstream signaling upon activation of 
either of the two receptors the regulation of the transcription factor NF-κB plays a pivotal role 
in TNFα signaling. However, only recently different and even opposite receptor specific 
effects have been reported (21,22), concluding a much more complex downstream signaling 
than simply NF-κB activation and consecutive modulation of inflammatory processes. As 
most information regarding TNFα signaling is derived from TNF-R1, the role of TNF-R2 is 
likely underestimated. 
 
 
Figure 1.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signaling pathways of TNFα through TNF-R1 and TNF-R2 
TNFα can act through different TNF-receptor-subtypes. Activation of NF-κB and subsequent 
induction of proinflammatory cytokines play a central role and are associated with both  
TNF-receptor signaling pathways (Figure modified after Holtmann and Neurath, Current 
Molecular Medicine 2004). 
 
 
 
1.1.4 TNFα’s crucial role in inflammatory processes 
Considering the downstream effects of the intracellular signaling pathways mentioned above 
it is easily conceivable why TNFα plays a central role in inflammatory diseases. While the 
original significance of TNFα in mediating necrosis in tumor cells could not lead to 
successful treatment options for cancer and remained limited to local therapy of limb soft 
tissue sarcoma (23), the role as a central player in inflammatory processes has become more 
and more evident. Finally as antibodies against TNFα have been used successfully in the 
treatment of several chronic inflammatory disorders including rheumatoid arthritis, 
ankylosing spondylitis, inflammatory bowel disease and psoriasis when other drugs failed, 
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TNFα’s role, not only in the development, but also in the maintenance of these diseases is 
undisputable (24,25). Different independent clinical studies show that inflammatory cytokines 
are not limited to the inflamed tissue but released to the systemic circulation leading to 
increased serum levels in these patients (26-30). 
 
 
 
 
1.2 Inflammation and cardiovascular diseases 
 
1.2.1 Links between inflammation and atherothrombotic diseases 
It is well known that inflammation plays a critical role in the development of atherosclerosis 
and its fatal outcomes, such as myocardial infarction and ischemic stroke (31-33). 
Proinflammatory cytokines including IFNγ, TNFα, IL-1β or IL-4 facilitate monocyte and 
lymphocyte recruitment to the vascular wall via induction of endothelial cell adhesion 
molecules, such as VCAM-1, even before plaque formation and contribute to progression of 
atherosclerotic plaque size (34,35). Lastly, also the disruption or fracture of the fibrous cap 
can be promoted by CD40L, IL-1 and TNFα (36-38). The pivotal role of inflammatory 
cytokines in atherosclerosis is further sustained by studies showing fewer atherosclerotic 
lesions in mice lacking TNFα or IL-1 (39,40). Hence, it is not surprising that patients with 
atherosclerosis and atherothrombotic disorders have been found to have increased serum 
levels of proinflammatory cytokines such as TNFα and IL-6 (41). 
 
 
 
Figure 1.2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vascular effects of TNFα 
TNFα signaling results in several cellular effects, which can promote the development of 
cardiovascular diseases (Figure modified after Zhang et al., Clinical Science 2009). 
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1.2.2 Vascular effects of TNFα 
In endothelial cells, which form the inner layer of blood vessels, a variety of inflammatory 
responses upon TNFα stimulation are described leading to endothelial activation, which could 
facilitate atherothrombosis. These include upregulation of certain leukocyte recruiting 
molecules, such as E-selectin, intracellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1) as well as release of chemokines including IL-8, MCP-1 and 
IL-10. Through activation of cyclooxygenase 2 (COX-2) and consecutive vasodilation by 
prostaglandin I2 (prostacyclin, PGI2) and increased vascular permeability even the classical 
clinical signs of inflammation “rubor”, “calor” and “tumor” can be observed as local effects 
of TNFα on endothelial cells (42). NF-κB translocation, increased production of ROS 
(reactive oxygen species) or influence on eNOS expression seem to be central steps in 
mediating the inflammatory effects (43-50). Figure 1.2 summarizes effects of TNFα on cells 
in the cardiovascular system. 
 
 
 
 
1.3 Platelet activation and arterial thrombosis in inflammation 
 
1.3.1 Activation of platelets and inflammation 
The scenario would be simplified thinking endothelial function alone is involved in 
inflammatory processes. Platelets are not only the final actors in the event of arterial 
thrombosis but are also playing an important role in the pathophysiology of atherosclerotic 
lesion formation, which in most cases creates the breeding ground for the thrombotic events. 
It is well described that platelets represent an important link between inflammation, 
atherogenesis and thrombosis (51-57). Platelets store several mediators and growth factors 
that play a role in several inflammatory processes, including CD40 ligand (CD40L), 
cyclooxygenase (COX), epithelial neutrophil activating protein 78 (ENA-78), interleukin 1β, 
macrophage inflammatory protein 1α (MIP-1α), platelet derived growth factor (PDGF), 
platelet factor 4 (PF-4), p-selectin, chemokine ligand 5 (CCL5, earlier also known as 
RANTES) and transforming growth factor β (TGF-β) (58). Similar to leukocytes, platelets can 
roll on the endothelium, which takes place particularly when the endothelium is activated 
(59). Under shear stress p-selectin and its counter-receptors PSGL-1 or GPIb and vWF are 
mediating platelet interaction with the endothelium. In the absence of further stimulation 
these interactions remain transient and platelets return to the circulation after seconds or 
minutes (57). The intact endothelium has several mechanisms to prevent adhesion of platelets. 
These include next to the release of nitric oxide (NO), which earlier was referred to as 
endothelium derived relaxing factor (EDRF), prostacyclin (PGI2) and adenosine (60-62) also 
the production of so called endothelium dependent hyperpolarizating factor (EDHF). The 
latter among other factors and substances include epoxieicosatrienoic acid (EET), which has 
recently characterized to affect platelets membrane potential through calcium dependent 
potassium channels (63,64). In the recent years our group could show that the inhibition of 
such endothelium released factors or potassium channels go along with increased platelet 
endothelium interaction and arterial thrombus formation in vivo (65-69). 
In the case of activated endothelium or loss of endothelium derived platelet inhibiting factors 
respectively, it comes to firm platelet adhesion to the endothelium through integrins and other 
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adhesion molecules, which mediate platelet activation and induction of surface exposure of  
p-selectin and the release of proinflammatory cytokines stored in α-granules. Among the long 
and permanently expanding list of adhesion proteins, growth factors, chemokines and 
coagulation factors, which exert pleiotropic effects on blood and vascular cells, next to  
p-selectin (70) the chemokines or chemokine-like factors IL-1β and CD40L should be 
mentioned, as their ability to induce endothelial inflammation is well investigated (71,72). 
Subsequently, stimulated endothelial cells via several mechanisms promote atherosclerotic 
plaque formation and finally more platelet activation. Thus platelets activate and maintain the 
vicious circle of inflammation (57). 
 
 
1.3.2 Arterial thrombus formation 
While under normal conditions, platelets are at rest and flow through blood vessels without 
interacting with other cells, once a site of vessel damage is detected, passing platelets adhere 
to the endothelium within seconds of the injury occurring. A number of components of the 
exposed subendothelium, first of all collagen and von-Willebrand-factor (vWF), but also 
fibronectin, laminin, and thrombospondin directly or indirectly mediate platelet adhesion 
through a range of platelet surface membrane receptors (51,73,74). Upon binding of receptors 
with their ligands, platelets change shape to increase their surface and intracellular signals 
cause degranulation of storage vesicles. These contain more platelet activating substances 
such as ADP (adenosine diphosphate) and serotonin. In addition thromboxane A2 is released, 
which also activates platelets. At the same time phospholipid membrane components on the 
platelets trigger the coagulation cascade resulting in the generation of insoluble fibrin, which 
provides stabilizing cross-links between platelets and exposed tissue (75,76). Platelet 
aggregation, which is following, together with the last stages of the coagulation cascade 
promote thrombus formation and growth eventually resulting in complete vessel occlusion. 
 
 
1.3.3 Clinical observations 
Clinical studies have pointed out several similar inflammatory and immunologic responses in 
atherosclerosis and rheumatoid arthritis, which is still representing the prototype of chronic 
inflammation (36,77). In both diseases a lot of common responses have been reported 
including increased markers of T- and B-cell-, macrophage- as well as mast cell activation 
and consequently also elevated serum levels of the proinflammatory cytokines TNFα and IL-6 
(41). Considering the crucial role of these cytokines in the pathophysiology of cardiovascular 
diseases it is not surprising that patients with rheumatoid arthritis are at increased risk for 
cardiovascular morbidity and atherothrombotic events such as acute myocardial infarction 
(36). More than one study in these patients could show a not ignorable increase in 
cardiovascular events, which could not be explained by traditional cardiovascular risk factors 
(78-82). However, anticytokine therapy in these patients has been reported both to reduce as 
well as to induce thromboembolic complications (83,84). 
 
 
1.3.4 TNFα and arterial thrombosis in vivo 
Putting clinical data and in vitro effects of TNFα observed in endothelial cells together could 
lead to the assumption that TNFα in the vascular bed might shift the balance to a more 
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prothrombotic state and deteriorate thrombotic events. Surprisingly Cambien et al. could 
show in an elegant study that TNFα has antithrombotic activity in vivo after short term 
treatment, a setting found for instance in the acute phase of sepsis. This was explained by an 
increase in NO production in the vascular wall (85). However this effect was reversible after 
two hours and there is a lack of studies referring to long term effects of TNFα concerning 
arterial thrombosis in vivo. 
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2 OBJECTIVE OF THE STUDY 
 
Considering an increased risk of atherothrombotic events in systemic inflammatory conditions 
with elevated serum levels of TNFα, but antithrombotic effects (albeit short term and 
reversible) in the only in vivo study for arterial thrombosis, the role of TNFα in this context 
remains unclear. Very limited data are available about the more long term effects and clinical 
data as well as in vitro effects on vascular cells rather support prothrombotic properties of the 
inflammatory cytokine. Moreover the underlying mechanisms specially referring to 
distinctive signaling through the different TNF-receptor subtypes are still to be elucidated. 
 
 
Therefore the aim of this study was to investigate the following issues: 
 
• Does TNFα increase arteriolar thrombosis and transient platelet-vessel wall-interaction 
in vivo? 
 
• If so, what are the underlying mechanisms? Is it due to a direct effect on platelets or 
through endothelium-mediated mechanisms? 
 
• What role do the TNF-receptor subtypes TNF-R1 and TNF-R2 play in this context? 
 
 
To address these questions the dorsal skinfold chamber microcirculatory model was used for 
in vivo assessment of arteriolar thrombus formation and transient platelet-endothelium-
interaction in wildtype and TNF-receptor deficient mice. 
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3 MATERIALS AND METHODS 
 
3.1 Chemicals 
Cell culture: Endothelial cell growth medium was purchased from Promocell (Heidelberg, 
Germany), fetal calf serum (FCS) and new born calf serum (NBCS) were from Biochrom 
(Berlin, Germany). Accutase was purchased from PAA (Cölbe, Germany) and Collagenase 
was from Roche (Basel, Switzerland). DMEM199 cell medium, EDTA, Penicillin-
Streptomycin, Trypsin and Trypsin-EDTA solution were from Sigma-Aldrich (Taufkirchen, 
Germany). 
 
Buffers and physiological solutions: CaCl2, D-Glucose, Glycerine, Glycine, Hepes, KCl, 
KH2PO4, MgCl2, Na2HPO4, NaCl and TRIS were purchased from Applichem (Darmstadt, 
Germany). 
 
Chemicals and dyes: CFDA-SE was from Bachem AG (Bubendorf, Switzerland), FACS-
lysing-solution was from BD (Franklin Lakes, NJ, USA), L-NAA was from Enzo Life 
Sciences (Lörrach, Germany), Prestained protein ladder was from Fermentas GmbH (St. 
Leon-Rot, Germany), Bromophenol blue was from Merck Chemicals Ltd. (Nottingham, UK), 
Nitrocellulose blocking membrane was from PEQLAB Biotechnologie GMBH (Erlangen, 
Germany), RLT buffer was from Qiagen (Hilden, Germany), Pefabloc was from Roche 
(Basel, Switzerland), Ilomedin was from Schering AG (Berlin, Germany). Murine leukemia 
virus reverse transcriptase was from Superscript; Invitrogen (Darmstadt, Germany), BCA 
reagens was from Thermo Scientific (Rockford, IL, USA). Bovine serum albumin (BSA), 
Acrylamid, Ammonium persulfate, Hydrogen peroxide, Luminol, Methanol, 
Paraformaldehyde, Sodium Dodecyl Sulfate (SDS), sodium-citrate, Temed and Tween were 
all purchased from Applichem (Darmstadt, Germany). Betamercaptoethanol, Cytochrom C, 
DAPI, Leupeptin, Na3VO4, Na4O7P2, NaF, P-cumaric acid, Pepstatin, Poinceau-S solution, 
RIPA-Buffer, Superoxide dismutase (SOD), Triton, Ferric chloride and FITC-Dextran were 
all purchased from Sigma-Aldrich (Taufkirchen, Germany). 
 
Cytokines and platelet agonists: Murine TNFα was from Chemicon International (Billerica, 
USA), human TNFα was from Reliatech GMBH (Wolfenbüttl, Germany), Thrombin 
Receptor Activator Peptide 6 (TRAP-6) was from Bachem AG (Bubendorf, Switzerland), 
collagen for platelet stimulation was from Nycomed GmbH (Konstanz, Germany) and ADP 
was purchased from Sigma-Aldrich (Taufkirchen, Germany). 
 
Anaesthetics: Fentanyl was from CuraMED Pharma GmbH (Karlsruhe, Germany), 
Medetomidinhydrochloride was from Orion Pharma (Espoo, Finland), Midazolam was from 
Ratiopharm GmbH (Ulm, Germany) and Sodium-Pentobarbital was purchased from Merial 
GmbH (Halbergmoos, Germany). 
 
Antibodies and primers: Anti-human p65 was from Santa Cruz Biotechnology (Santa Cruz, 
USA), Anti-mouse IgG alexa fluor 546 was from Invitrogen (Darmstadt, Germany), Anti-
rabbit IgG was from Calbiochem/Merck Chemicals Ltd. (Nottingham, UK), Anti-mouse  
GR-1-FITC and Rat IgG Negative control-FITC were purchased from EuroBioSciences 
GmbH (Friesoythe, Germany), Anti-human TNF-R1 and Anti-human TNF-R2 were from Cell 
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Signaling Technology (Danvers, MA, USA), Anti-human CD142-FITC, Anti-human  
CD62P-RPE, Anti-mouse-TNF-R1-RPE, Anti-mouse-TNF-R2-RPE, Mouse IgG Negative 
control-FITC, Hamster IgG Negative control-RPE and Mouse IgG Negative control-RPE 
were all purchased from Abd Serotec (Oxford, UK). Predesigned GAPDH and PAI-1 TaqMan 
primers were purchased from Applied Biosystems (Carlsbad, California, USA). 
 
 
 
 
3.2 Cell culture 
To investigate signaling and mechanisms on endothelial cells Human Microvascular 
Endothelial Cells (HMEC), which is an immortalized cell line (86), as well as primary Human 
Umbilical Vein Endothlial Cells (HUVEC) were used. 
 
 
Table 3.1 Cell media for HMEC 
 
HMEC growth medium (10%) HMEC starvation medium (1%) 
DMEM-199  DMEM-199 
+ Fetal calf serum (FCS) 10%  + Fetal calf serum (FCS) 1% 
+ Endothelial growth media 10%  + Penicilline/Streptamycine 1% 
+ Penicilline/Streptamycine 1%  pH 7.4 
pH 7.4  
 
 
Table 3.2 Cell media for HUVEC 
 
HUVEC growth medium (20%)  HUVEC starvation medium (1%) 
DMEM-199  DMEM-199 
+ New born calf serum (NBCS) 20%  + New born calf serum (NBCS) 1% 
+ Endothelial growth media 10%  + Penicilline/Streptamycine 1% 
+ Penicilline/Streptamycine 1%  pH 7.4 
pH 7.4  
 
 
Table 3.3 Collagenase A solution for detaching umbilical vein endothelial cells 
 
Collagenase A solution 
Collagenase type I (1700 U/mg) 1 g 
PBS+ ad 1000 ml 
The solution was passed through the filter Membrex 25 CA with a pore size of  
0.2 µm for sterilisation. 
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Table 3.4 Phosphate buffered saline (PBS) 
 
 PBS+  PBS– 
NaCl  8 g  8 g 
KCl  0.20 g  0.20 g 
Na2HPO4  1.15 g  1.42 g 
KH2PO4  0.20 g  0.20 g 
MgCl2  0.04 g  
CaCl2  0.50 g  
Distilled H2O  ad 1000 ml  ad 1000 ml 
pH 7.4   
 
 
 
3.2.1 Isolation and cultivation of human umbilical vein endothelial cells 
The human umbilical cords were provided by the obstetrical department of the Ludwig 
Maximilians University hospital of Munich. Written and informed consent was obtained from 
all patients. To isolate human umbilical vein endothelial cells (HUVEC) the vein in the 
umbilical cord was first rinsed with warm phosphate buffered saline supplemented with Ca2+ 
(PBS+, see table 3.4). To detach the endothelial cells from the vessel wall, the umbilical cord 
vein was incubated with 1 mg/ml collagenase A solution (table 3.3) in a humidified incubator 
for 10 minutes. The primary endothelial cells were then washed out of the vessel with 
HUVEC growth medium (table 3.2). Following collection of the cells, they were pelleted by 
centrifugation at 1200 rpm (Heraeus Megafuge 1.0R from Kendro, Langenseldbold, 
Germany) for 5 minutes at room temperature and subsequently washed with M199 medium. 
Finally, the purified primary endothelial cells were obtained in standard culture flasks in 
endothelial growth medium and left to grow at 37°C in a humidified incubator with 5% CO2. 
When reaching confluency, the cells were passaged and maintained in HUVEC growth 
medium at 37 °C with 5% CO2 in a humidified incubator. The primary HUVEC were used 
until the third passage only. Prior to the experiments cells were starved for 3 hours in HUVEC 
starvation medium (table 3.2). The investigation conforms with the principles outlined in the 
Declaration of Helsinki. 
 
 
3.2.2 Cultivation of human microvascular endothelial cells 
Human microvascular endothelial cells (HMEC) were provided by Ades et al. (86) and 
cultured in HMEC growth medium (table 3.1). The cells were maintained at 37 °C with 5% 
CO2 in a humidified incubator. Prior to the experiments cells were starved for 24 hours in 
HMEC starvation medium (table 3.1). 
 
 
3.2.3 Passaging of cells 
Confluent cells were washed once with warm PBS- followed by incubation with trypsin-
EDTA for approximately 2 minutes to allow the majority of the cells to detach from the cell 
culture dish. The enzymatic activity of trypsin was inhibited by application of the respective 
media containing at least 10% serum. Non attached cells were gently scraped off the dish with 
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a rubber scraper and the cell suspension diluted in the respective media followed by seeding 
onto new culture dishes. 
 
 
 
 
3.3 Animals 
All animal experiments were performed in Wildtype (WT)- or TNF-receptor deficient  
C57-BL/6 mice. WT mice were purchased from Charles River, Sulzfeld, Germany.  
TNF-R1-/- and TNF-R2-/- mice were originally obtained from the Jackson Laboratory (Bar 
Harbor, ME, USA), and TNF-R1-/-R2-/- mice were subsequently generated by cross-breeding 
of single TNF-receptor deficient mice. Animals were bred and kept at the animal department 
of the Institute of Physiology Munich, where they had a 12 hour light-dark cycle, were 
allowed to move freely in their cages and had free access to food and water. Ambient air 
temperature was 24 °C and air humidity 50%. All experiments were conducted in full 
accordance with the German animal protection law (TierSchG) paragraphs §1, §2 and §2a and 
approved by the government of Oberbayern. The investigation conforms with the Guide for 
the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). 
 
 
 
 
3.4 In vitro and ex vivo experiments 
 
3.4.1 Flow cytometry 
Flow cytometry (FACS) is a technique to analyze several cell parameters simultaneously. By 
letting cells pass one at a time through a focused laser beam, the scattering of the light gives 
information about the cell size, so called forward scatter (FSC) and the internal complexity of 
a cell, such as the extent of granulation, called sideward scatter (SSC). In addition to scatter, a 
cytometer is also able to detect fluorescence. By incubating cells with fluorescent labeled 
antibodies the measured fluorescence can give relative information about the density of the 
respective antigen on the cell. Flow cytometry was used to assess the expression of p-selectin 
and tissue factor on the surface of cultured endothelial cells, as well as to detect the presence 
of TNF-R1 and TNF-R2 on murine neutrophils. 
 
3.4.1.1 Assessment of surface molecules on endothelial cells 
HMEC or HUVEC were grown to sub-confluence, serum-starved for 24 hours or 3 hours 
respectively and incubated with sham or TNFα (5 ng/ml) for 30 minutes or 4 hours. After 
incubation cells were washed with PBS- and detached using Accutase. They were then 
collected, spun down (3000 rcf, 2 min) and resuspended in PBS+. After 10 minutes of fixation 
with 5% formaldehyde in PBS+, cells were washed again and then incubated using 
fluorescent-labeled antibodies (see table 3.5) or corresponding negative controls for  
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30 minutes at room temperature and darkness. They were then washed again and resuspended 
in PBS+ before fluorescence intensity was measured using a FACSCanto II flow cytometer 
(Becton Dickinson, USA). Data were analyzed using FACSDiva software (Becton Dickinson) 
and mean or median fluorescence, depending whether values were normally distributed or 
not, was calculated. 
 
Table 3.5 Antibodies used for FACS analysis of endothelial surface molecules 
 
Antibody Host Dilution Conjugate Company 
Anti-human-CD62P 
(p-selectin) 
Mouse 
(MC) 
1:20 FITC Abd Serotec, 
Oxford, UK 
Anti-human-CD142 
(tissue factor) 
Mouse 
(MC) 
1:20 RPE Abd Serotec, 
Oxford, UK 
 
 
3.4.1.2 Assessment of TNF-R1 and TNF-R2 on murine neutrophils 
Mice were anesthetized and whole blood was drawn with a 27G syringe by cardiac puncture. 
To avoid coagulation 3.13% sodium citrate was added 1:10. Whole blood was then incubated 
with fluorescent-labeled antibodies against TNF-R1 and TNF-R2 (table 3.6) or respective 
isotype control for 20 minutes at room temperature in the dark. Erythrocytes were lysed and 
white blood cells were fixed by adding 2 ml of FACS lysing solution for 10 minutes. Cells 
were spun down (700 rcf, 5 min) and washed with PBS+ before being analyzed on a 
FACSCanto II flow cytometer. Neutrophil identification was done by forward and sideward 
scatter and verified by staining with a FITC-labeled GR-1 (granulocyte antigen 1) antibody. 
 
 
Table 3.6 Antibodies used for FACS analysis of TNF-receptors on neutrophils 
 
Antibody Host Dilution Conjugate Company 
Anti-mouse-
TNFR1 
Hamster (MC) 1:10 RPE Abd Serotec, 
Oxford, UK 
Anti-mouse-
TNF-R2 
Hamster (MC) 1:10 RPE Abd Serotec, 
Oxford, UK 
Anti-mouse-GR1 Rat (MC) 1:10 FITC EuroBioSciences 
Friesoythe, 
Germany 
 
 
 
3.4.2 Immunofluorescent staining 
The principle is to detect an antigen with a primary antibody and to visualize it by staining 
with a so called secondary fluorescent-labeled antibody against the Fc-fragment of the 
primary antibody. This technique was used to localize the p65-subunit of NF-κB within 
endothelial cells. 
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3.4.2.1 Assessment of NF-κB translocation 
HUVEC were grown to sub-confluence in 8-well µ-slides for fluorescence microscopy (Ibidi 
GmbH, Martinsried, Germany), serum-starved for 3 hours and incubated with sham or TNFα 
(5 ng/ml, 4 hours). After incubation the cells were washed with PBS+ and fixed in 2% 
formaldehyde for 12 minutes. They were permeabilised by a 2 minute incubation with 0.2% 
Triton and unspecific binding of the antibody was blocked with 5% BSA for 1 hour. Cells 
were then incubated with an anti-p65-antibody (first antibody) for 45 minutes and DAPI  
(4′,6-Diamidin-2-phenylindol) to stain the nucleus of the cells, followed by incubation with a 
secondary fluorescent antibody for 30 minutes. After washing several times with 5% BSA the 
cells were analyzed by fluorescent imaging using a LSM II confocal microscope (Zeiss, 
Germany). 
 
 
Table 3.7 Antibodies used to detect the p65-subunit of NF-κB in endothelial cells 
 
 Antibody Host Dilution Company 
Primary 
antibody 
Anti-human-p65 
(monoclonal) 
Mouse 1:200 Santa Cruz, 
Heidelberg, Germany 
Secondary 
antibody 
Anti-mouse IgG 
alexa fluor 546 
Goat 1:200 Invitrogen, Eugene, 
Oregon, USA 
 
 
For quantification of the distribution of p65 between cellular cytosol and nucleus, cells were 
first identified in the microscopic transmission mode where five pairs of regions of interest 
(ROI) were placed in every image, of which one ROI was placed in the cytosolic 
compartment, the corresponding one in the nucleus of a cell. The size of a ROI was defined at 
5 µm2. After placement of ROIs the microscopic mode was switched to fluorescence within 
the very same image. The mean relative fluorescence in every ROI was then measured and the 
value of the ROI within the nucleus divided by the value of the ROI in the corresponding 
cytosolic compartment. For every condition of an experiment 10 different images were 
analyzed and the mean value of the ratios counted as one experiment. 
 
 
3.4.3 Western blotting 
Western blotting or immunoblotting is an analytical technique used to detect specific proteins 
in a given sample of cell or tissue lysate. Gel electrophoresis is used to separate denaturated 
proteins by the length of the polypeptide. The proteins are then transferred to a nitrocellulose 
membrane, where they can be detected using antibodies to the specific target protein. Western 
blotting in this study was used to see whether or which TNF-receptor subtypes are expressed 
in cultured endothelial cells. 
 
3.4.3.1 Cell lysates 
To obtain protein lysates the cells were washed once with PBS+ and immediately put on ice 
and lysed for 10 minutes using ice-cold lysis buffer (table 3.8). The cells were then scraped 
off the dish with a rubber scraper and passed repeatedly through a 29G needle. The debris was 
removed from the lysate by centrifugation at 10,000 g for 10 minutes and at a temperature of 
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4 °C. The protein concentration for the remaining solution was determined using BCA 
(bicinchoninic acid) protein assay reagent kit according to the manufacturer’s protocol. The 
protein lysates were either directly analyzed or kept frozen at -20 °C until further handling. 
 
 
Table 3.8 Buffer to lyse tissue culture cells grown in monolayer 
 
Lysis buffer 
KH2PO4 20 mM 
EDTA (Ethylenediaminetetraacetic acid) 1 mM 
Pefablock 1 mM 
Leupeptin 1 µM 
Pepstatin  1 µM 
NaF  50 mM 
Na4O7P2  40 mM 
Na3VO4  2 mM 
pH 7.3  
Before usage of the buffer, Triton X-100 was added to a final concentration of 1%. 
 
 
3.4.3.2 Assessment of protein concentration 
Protein concentration was measured using the BCA (bichinconinic acid) protein assay reagent 
kit and is based on the biuret reaction, where Cu2+ is reduced to Cu1+ by proteins in an 
alkaline medium. Addition of bichinconinic acid leads to a purple-coloured end product 
which can be detected colometrically at 562 nm. This end product is formed by the chelation 
of two molecules of BCA with one Cu1+ and is almost linear with increasing protein 
concentrations. 10 µl of protein lysate was added to a well in a 96 well plate formate prior to 
application of 200 µl BCA solution (mixed according to the supplier´s protocol). Every 
sample was measured in triplicates with SpectraFluor (Tecan, Crailsheim, Germany). A 
dilution series with BSA (2 mg/ml in distilled water) was run alongside with the protein 
lysates for the establishment of a standard curve. The mixture was incubated for 30 minutes at 
37 °C prior to measurement at 550 nm. 
The protein concentration was calculated according to the following formula: 
 
f(x)= m x + b 
 
where x has to be dissolved to reveal the protein amount in µg. m is the gradient of the 
standard curve, b is the axis intercept of the standard curve and f(x) is the absorbance data 
obtained. 
 
3.4.3.3 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
Proteins were thawed on ice and 25-40 µg were mixed with 1x loading dye, denaturated at 
100 °C for 5 minutes before separated on a 10% SDS-PAGE consisting of a 4% stacking gel 
and a 10% separation gel covered in 1x running buffer (composition of gel and buffers are 
listed in table 3.9). As a reference for protein size a prestained protein ladder solution was 
separated together with the proteins. The current was set to 35 mA and the proteins were left 
to run until the loading dye front was approximately 1 cm from the edge of the gel. 
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Table 3.9 Gel and buffers for electrophoresis 
 
Separation gel (10%): 
Distilled H20  20 ml 
Tris 1.5 M pH 8.8  12.5 ml 
Sodium dodecyl sulfate (SDS) 10%  0.5 ml 
Acrylamide/Bisacrylamide 30% / 0.8% (w/v)  16.6 ml 
Ammoniumpersulfate 10% (w/v)  0.25 ml 
Temed 0.025 ml 
 
Stacking gel (4%): 
Distilled H2O  6 ml 
Tris 0.5 M pH 8.8  2.5 ml 
SDS 10% (w/v)  0.1 ml 
Acrylamide/Bisacrylamide 30% / 0.8% (w/v)  1.3 ml 
Ammoniumpersulfate 10% (w/v)  0.05 ml 
Temed 0.01 ml 
 
For both gel solutions, H2O, Tris, Acrylamide/Bisacrylamide were mixed and degassed before 
addition of SDS, Ammoniumpersulfate and TEMED. Upon pouring the separation gel, a layer 
with butanol was added on top of the gel to prevent it from drying while polymerising. The 
butanol layer was meticulously washed off with distilled water before pouring the stacking 
gel on top of the separation gel. 
 
Loading dye (4x) 
Tris HCl pH 6.8  0.25 M 
SDS  8% 
Glycerine  40% 
Bromphenolblue  0.02% 
Mercaptoethanol  400 mM 
 
Running buffer (5x) 
Tris Base  123.8 mM 
Glycine  959.1 mM 
SDS  17.3 mM 
 
 
3.4.3.4 Blotting 
The separated proteins were then transferred onto a nitrocellulose membrane by 
electrophoresis using semi-dry blotting. For this, the nitrocellulose membranes together with 
filter papers were soaked in transfer buffer (table 3.10). The membrane and filters were 
stacked as a “sandwich” in the following order: filter paper, membrane, gel and filter paper. 
To check for equal amounts of protein and successful blotting, the membrane was incubated 
with Poinceau S solution (Sigma-Aldrich, Taufkirchen, Germany) which was removed by 
washing before further handling. To prevent unspecific binding of the antibodies the 
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membrane was blocked with blocking buffer for 30 minutes prior to a 1 hour incubation with 
the primary antibody diluted in the respective blocking buffer at 37 °C or at 4 °C over night. 
Unbound antibody was removed by washing 3 times for 5 minutes with TBS/T (table 3.10). 
The membrane was then incubated for 1 hour at room temperature or at 4 °C over night with a 
secondary antibody conjugated with horseradish peroxidase. After washing 3 times as 
described above, the enzymatic activity was detected upon addition of chemiluminescence 
detection kit for horseradish peroxidase according to the supplier’s protocol with a 
bioluminescence detection system attached to a digital camera (Sequoia). 
 
 
Table 3.10 Buffers for blotting 
 
Transfer buffer 
Glycine  39 mM 
Tris Base  48 mM 
SDS  0.037% 
Methanol 10% 
 
Tris buffered saline (TBS) (10x) 
Tris  24.2 g 
NaCl  58.44 g 
Distilled H2O  ad 1000 ml 
 
Tris buffered saline with Tween (TBS/T) 
TBS  1 x 
Tween 20  0.1% 
pH 7.6  
 
Blocking buffer 
Bovine serum albumine (BSA)  5% in TBS/T 
 
 
 
3.4.4 Quantitative real-time PCR  
Real-time polymerase chain reaction (RT-PCR), also called quantitative real time polymerase 
chain reaction is a method based on PCR, which is used to amplify and simultaneously 
quantify a targeted DNA molecule. If combined with reverse transcription real-time PCR can be 
used to quantify messenger RNA (mRNA) in cells or tissues. RT-PCR was used to assess 
mRNA-amount of plasminogen-activator-inhibitor 1 (PAI-1) in cultured endothelial cells. 
 
3.4.4.1 PAI-1 transcription in endothelial cells 
HMEC were grown to sub-confluence, serum-starved for 24 hours and incubated with sham 
or TNFα (5 ng/ml) for 30 minutes or 4 hours. After incubation cells were washed with PBS- 
and lysed quickly in 300 µl/3-cm-dish RLT buffer (Qiagen, Hilden, Germany) containing 1% 
beta-mercaptoethanol to eliminate ribonuclease released during cell lysis. RNA isolation was 
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performed immediately. Total RNA was isolated by RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s protocol including digestion of DNA during the procedure by RNase-Free 
DNase Set (Qiagen). Purity was checked by RNA-gel electrophoresis and absorbance at  
230 to 320 nm. For RT-PCR, 2 µg of isolated total RNA underwent random primed reverse 
transcription using a modified murine leukemia virus reverse transcriptase (Superscript; Life 
Technologies, Germany). In parallel, 2 µg aliquots were processed without reverse 
transcription to control for contaminating genomic DNA. 
Real-time PCR was performed on a TaqMan ABI 7700 sequence detection system (Applied 
Biosystems, Darmstadt, Germany) using heat-activated TaqDNA polymerase. GAPDH was 
used as reference housekeeping gene. All controls consisting of distilled H2O were negative 
for target and housekeeper. Quantification was done by the Pfaffl method (87). Commercially 
available pre-developed TaqMan reagents were used for the human target gene PAI-1 
(Applied Biosystems) and the endogenous control gene GAPDH (Applied Biosystems). The 
data shown in the figures are normalized to GAPDH. All measurements were performed in 
duplicates. 
 
 
3.4.5 Cytochrome C assay 
Cytochrome C is a heme protein and part of the mitochondrial electron transport chain. The 
ferricytochrome C can be directly reduced by superoxide (O2.-) to ferrocytochrome C. 
 
Fe3+ - Cyt.C + O2.- → Fe2+ - Cyt.C + O2 
 
This reduction leads to an increase in the absorbance spectrum of cytochrome C at 550 nm, 
which can be photometrically monitored. To detect the superoxide dependent part of 
cytochrome C reduction the difference in absorbance between samples incubated with or 
without superoxide dismutase has to be calculated. From Lamber-Beers-Law E = ε c d the 
concentration of produced superoxides can be determined (E = extinction; ε = extinction 
coefficient = 21 mmol/l cm−1 for cytochrome C at 550 nm; c = concentration; d = layer 
thickness). The cytochrome C reduction method was used to measure superoxide release of 
cultured endothelial cells. 
 
3.4.5.1 Assessment of endothelial superoxide release 
HUVEC were grown to sub-confluence and serum-starved for 3 hours before the experiments. 
To prevent modulating effects of NO all measurements were performed in the presence of the 
NO synthase inhibitor L-NAA (NG-Amino-L-argninine; 30 µmol/l), which was added to the 
cell medium 30 minutes before starting TNFα (5 ng/ml) stimulation. After 4 hours of 
treatment with TNFα or sham endothelial cells were incubated in colorless DMEM medium 
containing 40 µmol/l cytochrome C with or without SOD (200 units/ml). After 30 minutes the 
supernatant was removed, and the reduction of cytochrome C was spectometrally measured at 
550 nm (Ultrospec 2000, Amersham Pharmacia Biotech). Superoxide release was calculated 
as described above. 
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3.4.6 Platelet aggregation studies 
Platelet aggregation was measured in human or mouse PRP (platelet rich plasma) using the 
turbidimetric method described by Born (88). The optical aggregometer is a fixed wavelength 
spectrophotometer, where a beam of infrared light shines through the test sample (PRP) and 
another shines through the reference sample, which contains PPP (platelet poor plasma). 
When the PRP is stirred and stimulated by platelet agonists platelets start to form increasingly 
larger aggregates and the PRP begins to clear, allowing more light to pass through. The 
increase in light transmittance is directly proportional to the amount of aggregation and is 
amplified and recorded digitally. 
 
3.4.6.1 Platelet aggregation in human PRP 
Blood was drawn from the cubital vein of healthy human volunteers. Written informed 
consent was obtained from all blood donors. To prevent blood from clotting syringes were 
containing 10% of 0.11 mol/l sodium citrate. Human PRP was obtained by centrifugation of 
the whole citrated blood at 340 rcf for 15 minutes. PRP was incubated with TNFα (5 ng/ml) 
or sham for different times. PPP was obtained by centrifugation of PRP for 5 minutes at  
3000 rcf. Aggregation was started by adding ADP, collagen or TRAP to PRP under 
continuous stirring at 1000 rpm at 37 °C and measured by using a 2-channel-aggregometer 
(ChronoLog 490-2D, Havertown, PA, US). Percentage of maximal platelet aggregation was 
analyzed 6 minutes after addition of the stimulator using Aggrolink software (ChronoLog, 
USA). 
 
3.4.6.2 Platelet aggregation in murine PRP 
For platelet aggregation in mouse PRP the protocol was analogue to the procedure for platelet 
aggregation in human PRP with minor modifications. Whole blood was drawn by cardiac 
puncture from anesthetized mice with 27G syringes containing 1:10 sodium citrate to prevent 
coagulation. Murine whole blood was diluted with platelet resuspension buffer (table 3.12) to 
increase the volume and centrifugation was done at 130 rcf for 10 minutes. Platelet 
aggregation was then performed as described above. 
 
 
 
 
3.5 In vivo experiments 
 
3.5.1 Anaesthesia 
Animal surgical procedures were performed under short term anesthesia. As anaesthetics the 
drugs listed in table 3.11 were used. Anaesthetics were diluted in saline and administered 
intraperitoneally. After the experiments the animals were killed by injection of an overdose  
(2 g/kg) of sodium pentobarbital (Merial GmbH, Halbergmoos, Germany). 
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Table 3.11 Anaesthetics used for surgical procedures in mice 
 
Anaesthetic Dosis Company 
Midazolam 3 mg/kg Ratiopharm GmbH, Ulm, Germany 
Fentanyl 0.03 mg/kg CuraMED Pharma GmbH, Karlsruhe, 
Germany, 
Medetomidinhydrochloride 0.3 mg/kg Pfizer, Berlin, Germany; produced by 
Orion Pharma, Espoo, Finland 
 
 
 
3.5.2 Dorsal skinfold chamber implantation 
The dorsal skinfold chamber, which was developed at the Institute of Surgical Research, 
LMU Munich, Germany, is a well established model for microcirculation and already used in 
several studies in mice and other rodents (89-91). 
After the animals were anaesthetized as described above the hair on the back was removed by 
a hair clipper (Aesculap) and chemical depilation (Pilcamed, Schwarzkopf). Eyes were 
protected by application of Dexpanthenol ointment (Roche Germany, Grenzach-Whylen, 
Germany). After disinfection with alcohol 70% subcutaneous vessels were visualized 
diaphanoscopically and an extra manufactured chamber made up of two inversed plates of 
titanium was implanted. The chamber and the surgical instruments were sterilized prior to the 
surgical procedure. In the chamber a circular window is building the frame for an extra cut 
circular coverslip (ø 11.7 mm, Menzel, Braunschweig), which covers a circular area where the 
skin was removed on one side in a way that the skin of the opposite side is attached via 
adhesion and its blood vessels can be observed macroscopically and microscopically (see 
figure 3.1). All experiments were performed at a minimum of 24 hours after chamber 
implantation. Animals showing abnormal blood flow within the vessels of the dorsal skinfold 
chamber arterioles were excluded from the experiments. 
 
 
3.5.3 Carotid catheterization 
Animals with an intact microcirculation underwent carotid artery catheterization, which was 
needed for application of drugs or injection of isolated platelets to investigate platelet-vessel 
wall-interaction. 
The surgical procedure of catheterization was performed under the same short time 
anaesthesia protocol as described above. The right carotid artery was dissected from 
connective tissue and a 20 cm polyethylene tube (0.28 mm ID, 0.61mm OD; SIMS Portex, 
U.K.), which was prior thinned by mechanic elongation, was introduced in the common 
carotid. The tube was fixed to the artery and the subcutaneous tissue by a nonabsorbable 
surgical silk suture (5-0, Fine Science Tools, Heidelberg, Germany), placed subcutaneously 
and led out of the body on the back. The tube was flushed by saline, closed at the distal end 
and fixed to the dorsal skinfold chamber to avoid manipulation by the animals. 
 
 
 
 
3 Materials and methods 
20 
Figure 3.1 
 
 
 
Dorsal skinfold chamber mouse model 
The dorsal skinfold chamber is made up of two inversed plates of titanium, where a circular 
window is building the frame for an extra cut circular coverslip (the paper clip is shown as a 
size comparison) through which the microcirculation can be observed. We used this model 
to investigate arterial thrombosis and platelet-endothelium-interaction in vivo. The right 
upper panel shows a mouse carrying the implantation. 
 
 
 
3.5.4 Intravital microscopy 
Intravital fluorescence microscopy was performed using a modified microscope (Zeiss 
Axiotech Vario, Germany, figure 3.2). For the experiments mice were positioned in special 
plexiglas tubes, where the dorsal skinfold chamber can be fixed on the table not allowing 
mice to maneuver, which is required for the experiments. Fluorescence illumination was 
provided by an X-Cite® 120Q microscope light source system (Exfo life sciences division, 
Ontario, Canada) and images were recorded with a digital camera (AxioCam HSm, Carl Zeiss 
Germany). The exposure time for intravital recordings of blood flow or platelet-endothelium-
interaction was 60 ms. 
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Figure 3.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intravital microscopy of the microcirculation in the dorsal skin 
(A) A specially modified microscope linked to a digital camera was used for intravital 
imaging. Mice were positioned in a Plexiglas tube on the table in a way they were not 
allowed to maneuver the dorsal skinfold chamber during the experiments. (B) Fluorescent 
dyes allow visualization of blood flow (upper panel) or blood cells (e.g. platelets as shown in 
the lower panel) in the vessels. 
 
 
 
3.5.5 In vivo TNFα-stimulation 
For all intravital experiments TNFα was administered via the carotid catheter in a dose which 
was calculated to match serum concentrations of 5 ng/ml, a dose that caused effects in vitro 
and was previously used in studies of similar design (85). 
 
 
3.5.6 Intravital assessment of arterial thrombosis 
Intravital thrombotic vessel occlusion time was assessed in arterioles of WT- or TNF-receptor 
deficient mice in the dorsal skinfold chamber model. For induction of intraarterial thrombosis, 
the ferric chloride superfusion method was used (65,69). Before the experiments blood vessel 
flow was digitally recorded and regular blood flow was confirmed for all analyzed arterioles. 
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To visualize vessel lumina before vessel injury 50 µl of a 5% fluoresceine-isothiocyanate-
labeled dextran solution (FITC-Dextran, MW 150,000; excitation maximum λ = 490 nm, 
emission maximum λ = 520 nm) was infused via the carotid catheter. This way formation of 
thrombi was apparent as sparing in the fluorescent-labeled plasma (see figure 3.2, panel B and 
also figure 4.7, panel B). Injury to the vascular wall was then performed by application of  
30 µl of a ferric chloride solution (25 mmol/l) onto arterioles, using a standardized protocol. 
Movies were recorded until blood flow ceased or for at least 6 minutes if no vessel occlusion 
occurred. 
 
 
3.5.7 Mouse platelet isolation and staining 
For observation of in vivo platelet-endothelium-interaction by intravital microscopy platelets 
from donor mice were isolated and fluorescently labeled. Whole blood was drawn from 
anesthetized mice by cardiac puncture. To prevent blood from clotting syringes were 
containing 10% of sodium citrate. The citrated whole blood was spun at 130 rcf and the 
obtained PRP was incubated with the fluorescent dye CFDA-SE (5-Carboxyfluorescein 
diacetate; 17 µmol/l; excitation maximum λ = 492 nm, emission maximum λ = 517 nm) at 
dark for 30 minutes. Labeled platelets were then spun at 340 rcf and resuspended in a 
buffered calcium free physiologic solution (table 3.12). For centrifugation Iloprost (10 ng/ml) 
was added to prevent platelet activation. The ability of the isolated and stained platelets to 
aggregate was tested by platelet aggregometry (see 3.4.6). 
 
 
Table 3.12 Buffer for platelet resuspension 
 
Calcium free physiologic solution for platelet resuspension 
NaCl  4,03 g (138 mM) 
KCl 0,1 g (2,7 mM) 
NaHCO3  0,5 g (12 mM) 
NaH2PO4 0,03 g (0,4 mM) 
MgCl2 x 6H2O 0,1 g (0.49 mM) 
D-Glucose 0,45 g (5 mM) 
Hepes 0,6 g (5 mM) 
Ad 500 ml distilled water 
pH 7.35 
 
 
 
3.5.8 Intravital analysis of platelet-vessel wall-interaction 
For intravital studies of transient platelet interaction with the intact vessel wall isolated and 
fluorescent-stained murine platelets were injected via the carotid artery catheter and observed 
in the dorsal skinfold chamber model. Movie sequences of 30 seconds in 4-6 vessel segments 
in each animal were recorded and analyzed using AxioVision Software (Carl Zeiss, 
Germany). Vessels with abnormal flow were excluded from analysis. Velocities of single 
platelets were calculated with the formula v = ∆x/∆t being ∆x the assessed length of the 
platelet trace in single images and ∆t the exposure time of each single picture. Platelet-vessel 
wall-interaction (PVWI) was expressed in frequency histograms consisting of all platelet 
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velocities analyzed. Histograms were normalized to the maximum platelet speed within a 
vessel to exclude biasing influences of altered blood flow velocities between different 
arterioles. As a consequence a rightward shift in platelet velocity distribution within a 
histogram expresses less PVWI, whereas a leftward shift signalises increased PVWI at the 
arteriolar wall. Platelets with less than 5% of the velocity of the fastest platelets were defined 
as rolling platelets (see figure 3.2, panel B and also figure 4.8). A platelet was considered as 
firmly adherent when not moving for at least 10 seconds. 
 
 
 
 
3.6 Statistical analysis 
All statistical analyses were performed using Sigma Stat version 3.5. With normally 
distributed data, the Student’s t-test was used to compare two groups while the one-way 
ANOVA with Dunn’s correction was used for multiple comparisons. The Mann-Whitney 
Rank sum test was performed when comparing two groups which were not normally 
distributed, whereas comparisons between several groups not exhibiting normal distribution 
was achieved by analyzing the data with the analysis of variance on ranks. All data are 
presented as means +/- SEM (standard error of the mean). Differences were considered 
significant when the error probability level was P<0.05. 
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4 RESULTS 
 
4.1 Superoxide formation in endothelial cells 
To confirm previously described effects of TNFα on the cellular redox system the release of 
superoxide (O2·−) was measured using the cytochrom C assay in HUVEC. The 
photometrically recorded SOD (superoxide dismutase) sensitive fraction of cytochrome C 
(expressed as difference in absorbance) depicts the production of O2·− and was  
0.044 +/-0.01 /well in untreated cells, whereas it was significantly elevated to  
0.099 +/-0.03 /well in cells stimulated with TNFα for 1 hour in a dose of 5 ng/ml (n=15,  
P< 0.01 vs. control; figure 4.1). 
 
 
Figure 4.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Superoxide (O2
·−
) formation in cultured endothelial cells 
O2
·−
 formation was assessed by measuring the SOD (superoxide dismutase) sensitive fraction 
of cytochrome C reduction in HUVEC and was significantly increased when cells were treated 
with TNFα (5ng/ml, 1h). 
** P<0.01 vs. control (n=15) 
 
 
 
 
4.2 Translocation of the p65-subunit of NF-κB 
ROS such as O2·− can be involved in several pathways of intracellular signaling and are well 
known to activate the transcription factor NF-κB. Therefore the translocation of the p65-
subunit of NF-κB to the nucleus was assessed upon TNFα stimulation in cultured endothelial 
cells using immunofluorescence imaging. TNFα treatment (5 ng/ml; 1 h) of HUVEC resulted 
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in threefold increase in the ratio of relative fluorescence between nucleus and cytosol  
(3.28 +/-0.28) in comparison to controls, where it was 1.49 +/-0.16 (n=15, P<0.01 vs. control; 
figure 4.2). 
 
 
Figure 4.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Translocation of the p65-subunit of NF-κB in cultured endothelial cells 
The localization of the p65-subunit of the transcription factor NF-κB was analyzed in HUVEC 
by immunofluorescence imaging. (A) The immunofluorescent staining shows p65 localized 
mostly in the cytosol when cells were sham treated (left image, arrows), while a 
translocation to the nucleus could be observed in HUVEC stimulated with TNFα (right image, 
arrowheads). (B) Quantitative analysis shows an increased nuclear to cytosol ratio of p65-
fluorescence in cells treated with TNFα (5ng/ml, 1h). 
** P<0.01 vs. control (n=15) 
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4.3 Endothelial adhesion molecule expression 
Since the transcription factor NF-κB can upregulate several cell surface membrane molecules 
it was investigated whether and at what time TNFα leads to an up-regulation of the adhesion 
molecule p-selectin (CD62P), which is described to play a critical role in mediating platelet-
endothelium-interaction. The expression of p-selectin was measured on the cell membrane of 
HMEC and HUVEC by flow cytometric analysis. While p-selectin was barely detectable on 
the surface membrane of either non stimulated HMEC or only 30 minutes after stimulation 
with TNFα (5 ng/ml), the adhesion molecule was significantly upregulated in HMEC 
stimulated for 4 hours, where the mean of the relative fluorescence was elevated by  
10.2 +/-1.3 % compared to non stimulated cells (P<0.05, n=9; figure 4.3). To see whether 
TNFα leads to an increase in adhesion molecules also in primary endothelial cells, p-selectin 
surface expression was assessed in HUVEC. The effect of TNFα in these cells was much 
more striking, as the mean in the relative fluorescence was 50.4 +/-13.7 % higher than in 
untreated cells (P<0.05, n=5; figure 4.3). 
 
 
Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P-selectin (CD62P) expression on the surface of cultured endothelial cells 
The appearance of the adhesion molecule p-selectin was measured on the surface of HMEC 
and HUVEC by FACS analysis. In HMEC as well as in primary endothelial cells (HUVEC)  
p-selectin was significantly upregulated in cells being treated with TNFα (5ng/ml, 4h) 
compared to sham treated cells. 
RFU: Relative fluorescence units. 
* P<0.05 vs. control (n=5-9) 
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4.4 Tissue factor expression on endothelial cells 
To investigate whether mechanisms independent from the primary haemostasis could 
contribute to prothrombotic properties of TNFα the amount of tissue factor (CD142) 
expressed on cultured endothelial cells was measured. Tissue factor is a protein playing a 
crucial role in the activation of the extrinsic pathway of the coagulation cascade and is 
described to be upregulated under inflammatory conditions. Thus tissue factor was detected 
on the surface membrane of HMEC by FACS analysis after treatment with TNFα 5 ng/ml. 
The expression of tissue factor expression was slightly but not significantly decreased when 
stimulating cells for 30 minutes but raised up to the threefold after stimulating cells with 
TNFα for 4 hours (fold increase vs. baseline 3.35 +/-0.31 compared to non stimulated cells; 
P<0.01, n=10; figure 4.4). 
 
 
Figure 4.4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue factor on the cell membrane of cultured endothelial cells 
Tissue factor was detected on HMEC by FACS analysis. While no increase was found half an 
hour after stimulation with TNFα (5ng/ml), the expression on the cell membrane was 
significantly enhanced when cells were treated for 4 hours. 
RFU: Relative fluorescence units 
** P<0.01 vs. baseline (n=10) 
 
 
 
 
4.5 PAI-1 mRNA in endothelial cells 
As another primary haemostasis independent mechanism possibly contributing to 
prothrombotic effects of TNFα the transcription of PAI-1 (Plasminogen activator inhibitor 1) 
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was analyzed, which is one of the most potent inhibitors of fibrinolysis. Real time polymerase 
chain reaction (RT-PCR) was used to measure mRNA levels in cultured endothelial cells 
(HMEC) upon stimulation with TNFα 5 ng/ml for 30 minutes or 4 hours. The mRNA-ratio 
PAI-1 to GAPDH was slightly increased after half an hour but more than fivefold higher 
compared to baseline when stimulating endothelial cells for 4 hours (fold increase  
5.32 +/-0.47 vs. baseline; P<0.01, n=16; figure 4.5). 
 
 
Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAI-1 (plasminogen activator inhibitor 1) transcription in endothelial cells 
mRNA levels of PAI-1 were analyzed by RT-PCR after endothelial cells were stimulated with 
TNFα. In HMEC TNFα (5ng/ml) raised PAI-1 mRNA ratio slightly after 30min but a striking 
increase was observed after 4 hours. 
** P<0.01 vs. baseline (n=12) 
 
 
 
 
4.6 Platelet aggregation in PRP 
To consider direct effects of TNFα on platelets, aggregation was assessed in vitro in human 
PRP using light transmission aggregometry (Born’s method). Incubation of PRP with TNFα  
5 ng/ml for different times did not affect the ability of platelets to form aggregates upon 
stimulation with several commonly used platelet agonists. The ADP (5 µmol/l) dependent 
aggregation was not influenced by TNFα, neither after a short time of incubation nor after  
4 hours (figure 4.6, panel A). No changes could be seen with other stimuli like collagen  
5-10 µg/ml (figure 4.6, panel B) or TRAP (thrombin receptor activating protein) 5 µmol/l 
(figure 4.6, panel C) and TNFα itself did not cause aggregation either (data not shown). 
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Figure 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Platelet aggregation in human PRP (platelet rich plasma) 
Aggregation studies were performed in human PRP using light transmission aggregometry. 
(A) ADP (5µmol/l) dependent platelet aggregation at different time points was not changed 
when PRP was incubated with TNFα (5ng/ml) compared to the respective control PRP.  
(B) TNFα (5ng/ml, 30min) did not change aggregation when platelets were stimulated with 
different doses of collagen. (C) The representative image is showing characteristic platelet 
aggregation traces upon stimulation of PRP with TRAP (5µmol/l). No significant difference in 
either slope or maximal amplitude of the curves was apparent between TNFα and sham 
treated platelets. TRAP: Thrombin-receptor-activating-protein. (n=9-10, each) 
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4.7 Arterial thrombus formation in vivo 
To analyze the effect of TNFα on thrombus formation in vivo, next the time to thrombotic 
arterial vessel occlusion following injury to the vascular wall was assessed. Therefore the 
ferric chloride superfusion model in the dorsal skinfold chamber in the mouse was used. The 
time to complete microvascular thrombotic vessel occlusion upon injury was significantly 
accelerated from 259.5 +/-30.6 s in control animals to 157.8 +/-31.3 s in animals treated with 
TNFα 5 ng/ml (which was the calculated plasma level when given TNFα at a dose of  
0.4 µg/kg) 4 hours prior to the experiment (n=8, P<0.05 vs. control animals). Time to 
thrombotic vessel occlusion was not significantly accelerated compared to control animals 
when TNFα was given only half an hour prior to the experiment (241 +/-54.3 s; n=5; figure 
4.7 and table 4.1). 
 
 
Table 4.1 Thrombotic arterial occlusion time upon vessel injury in vivo after TNFα treatment 
(5ng/ml) in WT mice. Values are expressed as mean +/- SEM. 
 
Time of 
treatment (min) 
n Occlusion time (s) P-value vs. non treated 
animals 
0 13 259.5 +/-30.6 - 
30 5 241.0 +/-54.3 P=0.837 
240 8 157.8 +/-31.3 P<0.05 
 
 
 
 
4.8 Platelet-endothelium-interaction in vivo 
To have a more distinctive look at the endothelium transient platelet-vessel wall-interaction 
(PVWI) and firm adhesion of platelets to the vessel wall was investigated in vivo by intravital 
microscopy in the dorsal skinfold chamber. Following TNFα treatment (5 ng/ml calculated 
plasma level, 4 h) PVWI was enhanced as indicated by a leftward shift in platelet flow 
velocity distribution pattern and a significant decrease in the median platelet velocity from  
4.0 mm/s in control animals (n=3294 platelets, 5 different animals, range: 0.3-11.5 mm/s) to 
3.7 mm/s in TNFα treated animals (n=3239 platelets, 5 different animals, range:  
0.6-15.3 mm/s, P<0.05 vs. control animals; figure 4.8). When observing rolling platelets that 
were defined as platelets with a velocity of less than 5% of the maximal platelet velocity 
measured within a vessel, i.e. platelets directly interacting with the endothelium, their fraction 
relating to all analyzed platelets was only 0.1 +/-0.1 % in control animals and not significantly 
higher in TNFα treated animals, where it was 0.4 +/-0.6 % (n=5). 
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Figure 4.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arterial thrombus formation in vivo 
Time to thrombotic arterial vessel occlusion was measured in vivo in the ferric chloride 
superfusion model in the dorsal skinfold chamber in mice. (A) TNFα (5ng/ml) treatment for 
30 minutes did not enhance thrombotic vessel occlusion, but 4 hours after stimulation with 
the same dose time to complete thrombotic vessel occlusion was markedly accelerated (see 
also table 4.1). (B) The image shows thrombus formation in arterioles of the dorsal skinfold 
chamber after injury with ferric chloride. The white arrow is pointing at a thrombus, which is 
spared by the fluorescin-labeled plasma and almost occluding the vessel. Black arrows are 
indicating blood flow. 
* P<0.05 vs. non treated animals (n=8). 
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Figure 4.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Platelet-vessel wall-interaction (PVWI) in vivo 
Transient platelet interaction and firm adhesion to the endothelium was analyzed by 
intravital microscopy in the dorsal skinfold chamber in mice after injection of fluorescently 
labeled platelets from a donor animal. Quantitative analysis is performed by assessment of 
platelet velocities, which can be calculated from the length of the trace of a platelet in one 
single picture when knowing the exposure time. (A) Platelet velocities were displayed in 
frequency histograms. The median platelet velocity was decreased in mice treated with 
TNFα (5ng/ml, 4h; lower histogram) compared to control animals (upper histogram) as 
indicated by a leftward shift in platelet velocity distribution pattern concluding more PVWI in 
TNFα treated mice. Platelets with a velocity of less than 5% of the maximal platelet velocity 
(platelets left of the vertical bold line in the histograms, indicated by arrow) were defined as 
rolling platelets. The fraction of rolling platelets relating to all analyzed platelets was very 
low and not significantly different between animals stimulated with TNFα and control 
animals. (B) The images show digital records of carboxy-fluorescin labeled platelets in 
arterioles of the dorsal skinfold chamber. The lower image is showing increased platelet-
endothelium-interaction with rolling platelets (arrow). 
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4.9 TNF-receptor subtypes on endothelial cells 
Since TNFα is known to exert its effects through different receptor subtypes, namely TNF-R1 
and TNF-R2, the presence of these receptors on endothelial cells was checked for. Therefore 
western blotting of whole cell lysates of cultured endothelial cells was performed and the 
TNF-receptor subtypes were immunologically detected. Both TNF-R1 and TNF-R2 were 
present in HMEC and could be found also in primary endothelial cells (HUVEC) showing 
their characteristic protein band at 55 kDa for TNF-R1 and 75 kDa for TNF-R2 (figure 4.9, 
panel A). 
 
 
 
 
4.10 TNF-receptor subtype expression in WT and TNF-receptor KO mice 
Next it was investigated whether and to what amount the two TNF-receptor subtypes TNF-R1 
and TNF-R2 are expressed in WT, TNF-R1-/-, TNF-R2-/- and TNF-R1-/-R2-/- mice. Since 
TNF-receptors are known to play a role in white blood cells and these cells are relatively easy 
available, the density of TNF-R1 and TNF-R2 was measured on the surface of neutrophil 
granulocytes by FACS analysis of whole blood drawn by cardiac puncture. While on 
neutrophils of WT mice both receptor subtypes were present in a considerable amount, in 
TNF-receptor KO mice the respective receptors were successfully knocked out. In TNF-R1 or 
TNF-R2 deficient animals the expression of the respective non knocked-out receptor subtype 
was not significantly different from the expression observed in WT mice (fig. 4.9, panel C). 
 
 
 
 
4.11 Arterial thrombus formation in vivo in TNF-receptor KO mice 
After detection of the presence of both TNF-R1 and TNF-R2 on endothelial cells, distinctive 
effects by the two receptor subtypes regarding arterial thrombosis were analyzed after 
stimulation with their ligand TNFα. Time to complete thrombotic occlusion of the arteries 
upon exogenic injury of the vessel by ferric chloride superfusion was measured in the dorsal 
skinfold chamber model as described in the method section. The ability of TNFα (5 ng/ml,  
4 h) to accelerate arterial thrombus formation in vivo observed in WT mice (figure 4.7) was 
much more striking in TNF-R1-/- mice, where the mean vessel occlusion time after treatment 
with TNFα was reduced to 62.4 +/-13.1 s (n=5, P<0.05 vs. sham treated TNF-R1-/-; figure 
4.10, panel A). In TNF-R1-/- animals also the relative acceleration of thrombotic arterial 
vessel occlusion by TNFα was enhanced compared to WT animals. While the mean arterial 
vessel occlusion time was reduced by TNFα in WT mice by 37.5 +/-12.1 %, it was decreased 
by 71.1 +/-6.1 % in TNF-R1-/- mice after treatment with TNFα (n=5-8; P<0.05 vs. WT 
treated with TNFα; figure 4.10, panel B and table 4.2). In mice lacking TNF-R2 or both, 
TNF-R1 and TNF-R2, TNFα did not significantly accelerate arterial thrombus formation in 
vivo. Without treating animals with TNFα time to thrombotic vessel occlusion was not 
significantly affected in either of the TNF-receptor deficient animals compared to WT 
animals (fig. 4.10, panel A and table 4.2). 
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Figure 4.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNF-receptor expression 
Expression of TNF-R1 and TNF-R2 was assessed in cultured human endothelial cells by 
Western blotting and in white blood cells of WT and TNFR-KO mice by FACS analysis. (A) The 
representative blots show the characteristic protein bands for TNF-R1 and TNF-R2 detected 
at 55 kDa and 75 kDa respectively in whole cell lysates of both HMEC and HUVEC. (B) Murine 
neutrophils were identified in the Dot blot by FACS analysis of murine whole blood by 
forward (FSC) and sideward scatter (SSC). (C) Quantitative analysis reveals TNF-R1 and  
TNF-R2 were present on the surface of neutrophils in WT mice. In TNFR-KO mice the 
respective receptor was successfully knocked out, whereas the respective non-knocked-out 
receptor was expressed to a similar level as in WT animals. * P<0.05 vs. WT (n=4). 
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Table 4.2: Relative reduction of thrombotic arterial vessel occlusion time in vivo after TNFα 
treatment (5ng/ml, 4h) in TNFR-KO mice. Values are expressed as mean +/- SEM. 
 
Genotype n Relative reduction of time to 
vessel occlusion by TNFα (%) 
P-value vs. 
untreated animals 
WT 8 37.5 +/-12.1 P<0.05 
TNF-R1-/- 5 71.1 +/-6.1 P<0.05 
TNF-R2-/- 5 31.9 +/-16.3 P=0.11 
TNF-R1-/-2-/- 5 18.9 +/-20.4 P=0.43 
 
 
 
Figure 4.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Arterial thrombus formation in vivo in TNF-receptor KO mice 
(A) As already shown in figure 4.7 for WT mice the time to thrombotic arterial occlusion 
assessed upon vessel injury with ferric chloride was significantly accelerated with TNFα 
(5ng/ml, 4h; black circles, solid line). This effect was even stronger when TNF-R1 deficient 
mice were treated with TNFα (light gray circles, long-dashed line). In mice lacking TNF-R2 
only (dark gray circles, short-dash line) or both TNF-receptor subtypes (white circles, spotted 
line) TNFα did not significantly affect arterial thrombosis. (B) In TNF-R1-/- mice (grey bar) 
also the relative acceleration of arterial thrombus formation by TNFα was significantly 
stronger compared to the relative acceleration by TNFα in WT mice (black bar). 
* P<0.05 vs. respective sham treated animals (n=5-10); # P<0.05 (n=5)  
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4.12 Platelet-vessel wall-interaction in vivo in TNF-R1-/- mice 
Considering TNF-R1 deficient mice showing enhanced arterial thrombus formation upon 
TNFα stimulation in the ferric chloride superfusion model platelet-vessel wall-interaction in 
vivo in this genotype was investigated in our model in the dorsal skinflold chamber. 
The leftward shift in platelet velocity pattern indicating increased platelet-endothelium-
interaction in WT mice after treatment with TNFα (5 ng/ml calculated plasma level, 4 h) in 
the group of TNF-R1-/- mice treated likewise was much more prominent. Median platelet 
velocity in these animals was significantly lower than in WT animals treated in the same 
manner (figure 4.11, panel A and table 4.3). In these animals TNFα raised the fraction of 
rolling platelets (defined as those platelets with a velocity below 5% of the maximum platelet 
velocity), which was only 0.4 +/-0.3 % in WT-mice, but 4.1 +/-1.0 % in TNF-R1-/- mice 
treated with TNFα (n=5, P<0.01 vs. WT; figure 4.11, panel B and table 4.3). When comparing 
maximum platelet velocities in the analyzed vessels between animals as an approximate 
measure of flow velocity, no significant difference was found between the genotypes. 
 
 
Table 4.3 Platelet-endothelium-interaction after TNFα treatment (5ng/ml, 4h) in vivo in WT 
and TNF-R1-/- mice. Values are expressed as median and range for platelet velocity and as 
mean +/- SEM for fraction of rolling platelets. 
 
Genotype n Analyzed 
platelets 
Platelet velocity 
(mm/s) 
Rolling platelets 
(fraction in %) 
WT 5 3239 3.7 (0.6-15.3) 0.4 +/-0.6 
TNF-R1-/- 5 3091 2.7 (0.1-13.0) 4.1 +/-1.0 
 
 
 
 
4.13 Platelet aggregation in TNF-R1-/- mice 
To check whether the prothrombotic effects observed in TNF-R1-/- mice could be due to a 
direct activation of platelets platelet aggregation studies were performed ex vivo in PRP from 
TNF-R1-/- mice. Platelets from these animals showed no differences in the ability to 
aggregate with or without prior incubation with TNFα 5 ng/ml to different stimuli including 
ADP (n=5; figure 4.12), collagen and TRAP and in different time ranges. TNFα alone did not 
induce aggregation in the murine PRP either. 
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Figure 4.11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Platelet-vessel wall-interaction (PVWI) in vivo in TNF-R1 deficient mice 
Platelet-endothelium-interaction was analyzed by intravital microscopy in the dorsal skinfold 
chamber after injection of fluorescently labeled platelets from a donor animal. (A) Platelet 
velocities are displayed in frequency histograms. The left shift in the distribution pattern of 
platelet velocities when TNF-R1-/- mice (lower histogram) were treated with TNFα (5ng/ml, 
4h) indicates more PVWI in these animals compared to WT animals (upper histogram) 
treated likewise. Those platelets with a velocity of less than 5% of the maximal platelet 
velocity, which are settled on the left of the vertical bold line in the histograms (indicated by 
arrow), were defined as rolling platelets and were significantly more frequent in the TNF-R1 
deficient group compared to the WT group if both were treated with TNFα. (B) When 
quantifying rolling platelets after TNFα treatment the fraction related to all analyzed 
platelets was significantly higher in mice lacking TNF-R1 (gray bar) compared to WT animals 
(black bar; see also table 4.3). 
* P<0.05 vs. WT mice (n=5) 
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Figure 4.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Platelet aggregation in PRP (platelet rich plasma) of TNF-R1 deficient mice 
PRP from WT and TNF-R1-/- mice was obtained from anticoagulated whole blood drawn by 
cardiac puncture and aggregation studies were performed using light transmission 
aggregometry. (A) TNFα did not influence ADP (20μmol/l) dependent platelet aggregation ex 
vivo in PRP from either WT or TNF-R1 deficient mice. The platelet aggregation maximum 
after incubation with TNFα (5ng/ml, 30min) was not significantly different in PRP from  
TNF-R1-/- mice compared to PRP from WT mice either. (B) The representative traces upon 
stimulation with ADP for WT (blue trace) and TNF-R1-/- mice (black trace) show a similar 
pattern of aggregation (n=5). 
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5 DISCUSSION 
 
5.1 TNFα and atherothrombotic disease 
Cardiovascular diseases are still the number one of death causes in developed countries and 
not only of scientific but also of economical interest. The understanding of the 
pathophysiology of these diseases is fundamental to approach this immense challenge for our 
health systems. 
It is now more than a decade ago, when Russ et al. claimed atherosclerosis to be an 
inflammatory disease (31) and hereby got a ball rolling to put cardiovascular diseases more 
and more in a wider spread context. The role of inflammation has not only shown to be 
essential in the development of cardiovascular diseases but also seems to influence heavily 
the fatal endpoints as myocardial infarction and stroke (32,33). As these events are lastly the 
consequence of arterial occlusion by thrombus formation, treatment and prevention so far has 
focused primary on direct inhibition of platelets, but also on improving endothelial 
dysfunction e.g. by blocking deleterious effects of Angiotensin-2 (ACE-inhibitors) or 
catecholamines (betablockers) or on lowering lipid levels (statines). However, modifying the 
inflammatory component of cardiovascular diseases so far has not been established in routine 
medical treatment. 
In the classical chronic inflammatory disorders as rheumatoid arthritis or inflammatory bowel 
diseases the modulation of inflammatory cytokines such as TNFα or IL-1 has been very 
successful, especially when the traditional anti-inflammatory drugs are failing. The reasons 
why anticytokine therapy so far could not succeed in the treatment and prevention of 
cardiovascular diseases (92) can be numerous and based on scientific as well as economical 
aspects. Nevertheless this approach remains of pharmacological interest since the role of 
inflammation in these illnesses has more and more turned out to be of great importance – even 
if more complex as initially expected. 
 
The aim of this study was to address the role of TNFα as one of the best described 
inflammatory cytokines and to characterize its effects concerning arterial thrombus formation 
and platelet activation, the latter being also important in the early pathophysiological steps of 
atherosclerotic plaque formation. The role of platelets and endothelial cells in these processes 
was analyzed and the specific signaling by the different TNF-receptor subtypes TNF-R1 and 
TNF-R2 was elucidated. 
 
 
 
 
5.2 The dorsal skinfold chamber as a mouse model to investigate arterial 
thrombosis and platelet-vessel wall-interaction in vivo 
As described in detail in the methods section intravital microscopy was used as a tool to study 
arterial thrombus formation and platelet-vessel wall-interaction in vivo. The dorsal skinfold 
chamber mouse model allows a direct view into the microcirculation and effects can be 
observed for an extended time period (91). It has been used for a number of applications 
ranging from investigation of tumor growth to the effects of vasoactive agents (89-91). 
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Compared to other in vivo models, anesthesia is not required during the experiments so that 
bias by anesthetic drugs must not be considered. A disadvantage of this model in the setting 
used here is that it assesses effects on the microcirculation, whereas atherothrombosis is 
predominantly a problem of large vessels. Indeed, findings from the microcirculation need to 
be applied very carefully to other vascular beds. However, the model used in this study has 
been successfully used for similar studies before (65,66,69) and the findings did very well 
correlate with the pathophysiology and clinical observations in larger vessels (93,94). Finally 
the microcirculation has the advantage that processes can be observed via intravital 
microscopy and digitally recorded in a very high quality so that it is possible to visualize and 
analyze also very moderate effects in a precise and selective manner. 
 
 
5.2.1 Assessment of arterial thrombosis in vivo 
A range of murine thrombosis models in different vascular beds are described in the literature 
including chemical injury, photochemical induced oxidation injury (light-dye technique) 
(95,96), direct laser injury, temporary ligation of the vessel, intraluminal mechanical as well 
as electrical injury (97). In principle, almost every technique can be applied in the 
microcirculation, however, some methods such as ligation of these small arterioles or venules 
are very difficult to apply without damaging the vessel and so causing relevant bias. 
Chemically induced vascular injury by ferric chloride superfusion is a well approved model 
for arterial thrombosis, which is reliably applicable also for very small vessels and established 
in our group (65,69). It must be said, however, that superfusion in the microcirculation does 
not allow very selective injury, i.e. all cells of the vessel wall are hit by the chemical. The 
technique was applied in the in vivo model, where FITC-dextran was used as a fluorescent 
dye to stain plasma so that the progressive growth of thrombi can be visualized as increasing 
negative contrast in the labeled plasma. 
 
 
5.2.2 Analysis of platelet-endothelium-interaction in vivo 
Based on the dorsal skinfold chamber model in our group a method to analyze platelet-
endothelium-interaction was developed (65,69). Platelet activation is not only relevant when 
it comes to vascular injury, but in the last years activation of platelets and transient interaction 
with the endothelium have also been described to influence the development of 
atherosclerotic lesions (51-58). Digital records of high quality using a high speed camera 
permit to selectively investigate these transient interactions of labeled platelets from a donor 
animal with the intact endothelium. 
To quantify platelet-interaction with the vascular wall platelet velocities were calculated as 
described in detail in the method section and platelet velocity profiles within a vessel were 
analyzed. There is no fixed definition of a rolling platelet in a movie sequence. In this study 
those platelets were defined as “rolling platelets” that showed a velocity of less than 5 % of 
the velocity of the fastest analyzed platelet within a vessel representing the blood flow. 
Hereby a more strict definition of rolling was applied compared to that used in other studies 
of platelet-vessel wall-interaction (98). The definition reflects the intention to only detect 
those platelets that really interact considerably with the endothelium through cell surface 
adhesion molecules such as p-selectin or GPIb/vWF and hereby play a role in the 
pathophysiology of atherosclerosis. 
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A limitation of this method is certainly that the analyzed platelets are from another individual. 
Even if in vivo selective targeting of specific platelet surface antigens by antibodies is 
possible, it would not be sufficient for adequate visualization and analysis of platelet rolling 
on the vessel wall. However, the platelet isolation from allogenous donors is well established 
and activation by the isolation or staining processes as well as the ability of the platelets to 
aggregate was tested by ex vivo platelet aggregation studies. Moreover by using platelets from 
donor animals, there is the possibility to investigate platelet-endothelium-interaction between 
individuals with different genetic backgrounds and thereby to find out something about 
whether platelet or endothelium dependent factors are contributing to the findings. 
Another point to mention is the role of leukocytes, which in the model used in this study are 
not stained and therefore not visible for analysis. Since white blood cells are well known to 
interact with platelets and their interaction with platelets and the endothelium is playing an 
important role in the development of atherosclerotic lesions (74,99-101) this would be an 
interesting aspect and should be subject for further experiments. 
 
 
 
 
5.3 TNFα – pro- or antithrombotic? 
There is compelling evidence that TNFα has prothrombotic properties from several clinical 
studies proclaiming an increased risk for atherothrombotic events in diseases associated with 
high plasma levels of TNFα (36,41,77-82) independently from the classic cardiovascular risk 
factors. Additionally a lot of in vitro studies in endothelial cells have been published, which 
show effects of TNFα potentially favoring prothrombotic effects (43-50). However, there is a 
lack of in vivo studies concerning direct links between inflammation and atherothrombotic 
diseases. Surprisingly, in the only in vivo study investigating the influence of TNFα on 
arterial thrombosis Cambien et al. describe an antithrombotic effect of TNFα after exogenous 
administration (85). This effect was observed after short term administration of TNFα peaking 
30 minutes after application and is explained by a rapid generation of NO in the vessel wall. 
The antithrombotic effect was fully reversed after 2 hours and the observation was not 
extended for a longer period. Even if these observations are not necessarily inconsistent with 
findings of clinical studies there is a need for further studies to clear this problem. 
 
In the in vivo model of arterial thrombosis used in this study a clear prothrombotic effect of 
TNFα could be observed. Time to thrombotic vessel occlusion upon injury was significantly 
accelerated after animals had been stimulated systemically with TNFα for 4 hours. These 
prothrombotic properties were not seen, when stimulating mice for only half an hour. When 
analyzing platelet interaction with the intact endothelium after stimulation with TNFα, i.e. 
without endothelial injury, a slight leftward shift in the platelet velocity histogram was 
noticed, indicating a tendency towards increased communication of platelets with the 
endothelium. However the amount of rolling platelets, i.e. platelets mechanically interacting 
with endothelial cells through surface adhesion molecules such as p-selectin or GPIb and 
vWF, was not changed by TNFα. 
 
Different paramenters in endothelial cells and platelets potentially resulting in increased 
arterial thrombosis or favoring interaction of platelets with the endothelium were investigated. 
In cultured human endothelial cells activation of NF-κB, release of O2·− and regulation of 
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adhesion molecules as well as parameters independent from the primary haemostasis were 
assessed upon stimulation with TNFα. Indeed, increased production of O2·− and translocation 
of the p65-subunit of NF-κB already could be measured after an hour of incubation with 
TNFα. After 4 hours – but not after 30 min – of stimulation with TNFα there was a significant 
increase in endothelial surface membrane p-selectin, which is well known to play an 
important role in platelet-endothelium-interaction (59,98,102). Also effects not related to the 
primary haemostasis, which are going along with prothrombotic effects, such as the 
expression of tissue factor (CD 142) on endothelial cells and endothelial mRNA of PAI-1 
were manifold increased upon TNFα stimulation. Similar to p-selectin expression these 
parameters were not elevated after only half an hour of stimulation but markedly after 4 
hours. 
 
Taken together, these results show prothrombotic properties of TNFα in vivo. These effects 
could not be observed after a short stimulation with TNFα of only half an hour but arterial 
thrombus formation was clearly enhanced after 4 hours. Also the observations in endothelial 
cells are highly supporting evidence for prothrombotic properties of TNFα. 
The in vivo data do well support clinical studies reflecting correlations between chronic 
inflammatory disorders and atherothrombotic events and the endothelial effects agree with 
those already described in the literature. TNFα exerted prothrombotic effects in vivo only 4 
hours after stimulation and also the in vitro effects on endothelial cells as p-selectin or tissue 
factor upregulation and increased mRNA levels of PAI-1 were not seen after half an hour of 
incubation with TNFα but after 4 hours. 
The results did not confirm antithrombotic effects of TNFα observed in another in vivo study 
of arterial thrombosis by Cambien et al. (85). In the mentioned study antithrombotic effects 
were due to a rapid release of endothelial NO and fully reversed after two hours. Acute 
elevation of TNFα can be found e.g. in the acute phase of sepsis, but chronic inflammation is 
associated with ongoing increased levels of inflammatory cytokines. The results obtained in 
this study do not put potential antithrombotic effects of TNFα after short term administration 
into question, but rather refer to the more long lasting effects of the cytokine as found in 
chronic inflammatory disorders. Indeed, several effects of TNFα were not observed after half 
an hour but already after four hours. After a short time of stimulation TNFα in our model did 
not reveal any significant effects – neither pro- nor antithrombotic. Local differences between 
distinctive vascular beds could be responsible for this, since antithrombotic effects were 
described in mesenteric arterioles while the experiments in this work were performed in the 
microvascular bed of the dorsal skin. It should also be said, that our in vivo model of arterial 
thrombosis is rather eligible to detect prothrombotic than antithrombotic effects. 
 
 
 
 
5.4 What are the mechanisms underlying the prothrombotic effects of 
TNFα? 
The striking prothrombotic effects of TNFα in the in vivo model raise the question about what 
mechanisms are responsible for the observations. The main issue is whether accelerated 
thrombus formation is due to a direct effect of TNFα on platelets or based on indirect, 
endothelium-mediated mechanisms. The endothelium is building the inner layer of a blood 
vessel so that endothelial cells can directly interact or communicate with the blood cells. An 
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intact endothelium is necessary to keep thrombosis and thrombolysis, coagulation and 
fibrinolysis in balance. Several pathological conditions can affect endothelial cells and 
thereby influence the physiological equilibrium. Numerous studies have investigated effects 
of TNFα on endothelial cells in vitro. When looking at the cytokine’s properties being able to 
influence thrombus formation or to activate platelets, effects as downregulation of eNOS, 
increased production of ROS and activation of NF-κB are well described (43-50). In this 
study a cultured endothelial cell line (HMEC) as well as primary endothelial cells (HUVEC) 
were used to investigate effects potentially resulting in increased susceptibility for arterial 
thrombosis. Additionally direct effects of TNFα on platelets were considered. 
 
 
5.4.1 ROS formation and activation of NF-κB in endothelial cells 
Reactive oxygen species (ROS) are molecules containing oxygen that are highly reactive due 
to the presence of unpaired electrons. ROS are not only a product of the normal oxygen 
metabolism, but have also important roles in cell signaling by functioning as second 
messengers (103,104). An increase in ROS levels, also known as oxidative stress, which 
happens for instance upon environmental stress such as UV or heat exposure can lead to 
significant cell damage. Endothelial or platelet derived ROS can exert prothrombotic effects 
by directly activating platelets or decreasing the threshold for platelet activation (68,105,106). 
As a scavenger of endothelial and platelet derived NO, earlier also referred as EDRF 
(endothelium derived relaxing factor), O2·− has prothrombotic properties by decreasing the 
bioavailability of this very important inhibitor for platelets under physiological conditions 
(48,107,108). Also in their function as intracellular messengers e.g. by activation of the 
transcription factor NF-κB (109,110) O2·− can contribute to endothelial dysfunction and 
therefore lead to a more prothrombotic state. In this study a markedly elevated formation of 
O2·− in HUVEC and a translocation of the p65-subunit of NF-κB could be found after 
incubating the cells with TNFα. The transcription factor NF-κB is well described to play a 
role in many inflammatory processes and its activation is also known to induce up-regulation 
of cell adhesion molecule expression (50) mediating platelet-endothelium-interaction. 
 
 
5.4.2 Upregulation of endothelial adhesion molecules 
Considering activation of NF-κB, an interesting question was whether TNFα would influence 
endothelial surface membrane adhesion molecules. Indeed, a considerable increase in  
p-selectin expression on HMEC as well as on HUVEC could be measured after 4 hours of 
incubation with TNFα. Endothelial p-selectin is known to play an essential role in platelet-
endothelium-interaction and is best described in the context of platelet rolling (59,98,102). 
Elevated amounts of p-selectin on the surface of endothelial cells can promote rolling and 
adhesion of platelets and hereby not only facilitate thrombus formation but also contribute to 
the development and progression of atherosclerotic lesions. 
 
 
5.4.3 Mechanisms other than primary hemostasis 
As mentioned in the introduction, arterial thrombus formation and following occlusion of the 
vessel is a very complex pathophysiological process, where next to platelets and endothelial 
cells also other influencing factors play a role. The plasmatic coagulation, also referred to as 
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secondary hemostasis, interacts with the primary hemostasis and the cleavage of fibrinogen 
by thrombin is necessary to stabilize a thrombus. 
Tissue factor is a protein playing a crucial role in the activation of the extrinsic pathway of the 
coagulation cascade (111). In a physiological environment endothelial cells express, if at all, 
very little tissue factor. However, the protein is described to be upregulated under 
inflammatory conditions (112-114). The results in this study agree with data in the literature 
and are showing a severalfold upregulation of tissue factor on endothelial cells in vitro after  
4 hours of TNFα stimulation. By binding activated coagulation factor VII, tissue factor 
activates the extrinsic pathway of the coagulation cascade and contribute to the growth and 
stabilization of a thrombus. Additionally tissue factor can induce the generation of 
microparticles, which are recruited to the site of an injury and can contribute to increased 
thrombin generation (111). 
Another protein which independently from primary hemostasis could affect arterial 
thrombosis is plasminogen activator inhibitor 1 (PAI-1). It is the major physiologic inhibitor 
of tissue-type plasminogen activator in plasma, which serves as an endogenous defense 
mechanism to prevent intravasal thrombosis (115). PAI-1 is elevated in a variety of clinical 
situations that are associated with increased risk of ischemic cardiovascular events (116-120). 
Consistently with similar experiments previously described (121,122), the experiments 
performed in this study showed an increase of PAI-1 mRNA in human endothelial cells upon 
stimulation with TNFα after 4 hours. Increased PAI-1 levels can shift the hemostasiologic 
balance to the prothrombotic side by inhibiting plasminogen activation and consequently 
fibrinolysis and therefore display another explanation for TNFα’s prothrombotic properties. 
 
 
5.4.4 Direct effects of TNFα on platelets 
Prothrombotic properties of TNFα could also be due to a direct effect on platelets. Therefore 
platelet aggregation was performed in PRP (platelet rich plasma). Different platelet agonists 
such as ADP, TRAP and collagen were tested and no changes in platelet aggregation could be 
seen when the PRP was preincubated with TNFα. Stimulation for a time of 4 hours, where the 
endothelial effects of TNFα were most pronounced did not show any difference in platelet 
aggregation either and TNFα itself did not induce aggregation. There are descriptions of weak 
direct activation of platelets by TNFα (123-125). Platelets are indeed described to express 
TNF-R1 and TNF-R2 even if (at least under physiological conditions) in a very low amount 
(126). However, in this study no influence of TNFα on platelets could be observed, neither in 
human nor in murine PRP. 
 
 
These data clearly speak for the endothelium being the main mediator of the observed 
prothrombotic effects exerted by TNFα in our experiments. 
All of the effects of TNFα observed in endothelial cells in vitro can increase platelet 
responses, activation or aggregation. While increased endothelial superoxide production and 
NF-κB activation indirectly contribute to a greater susceptibility for arterial thrombosis (68), 
elevated p-selectin directly facilitate the interaction of platelets with the endothelium 
(98,111). Tissue factor and PAI-1 as important regulators of the plasmatic coagulation finally 
can promote the growth and stabilization of thrombi (112,115). The fact that in additionally 
performed aggregation studies in PRP TNFα did not have an impact on platelet aggregation, 
endorses the hypothesis of an endothelium mediated pathomechanism. These observations do 
fit well to the findings in our in vivo model of arterial thrombosis after vessel injury, where a 
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clear prothrombotic effect was mediated by TNFα. However, one must be very careful when 
transferring data obtained under the bench to the living organism, and indeed it must be said 
that from the in vivo findings a direct effect of TNFα on platelets cannot be excluded. The 
environment, where platelets roll and adhere on the endothelium and finally aggregate and 
form thrombi in vivo, is much more complex than any platelet aggregation measurements ex 
vivo. Nevertheless our in vivo model of platelet-vessel wall-interaction, where a slight 
increase in transient interaction of freshly isolated (i.e. non TNFα treated) platelets with a 
pretreated endothelium was apparent, demonstrates that TNFα can lead to a prothrombotic or 
platelet activating state by stimulating endothelium alone. In vitro observed findings cannot 
be seen isolated in vivo, either. Effects as increased superoxide production or NF-κB 
activation are involved in numerous processes and signaling pathways in several cellular 
systems and tissues (50,103,108), but some of their abilities can help to explain prothrombotic 
properties of TNFα in vivo. 
Taken together the observed prothrombotic effects in this study are mediated mainly through 
the endothelium rather than through direct effects on platelets. 
 
 
 
 
5.5 What TNF-receptor subtype is responsible for the effects? 
It is well known that TNFα is acting through different receptor subtypes and distinctive 
signaling upon activation of either receptor has been described (1,5,6). The signaling 
pathways mediated by the two receptors are complex and partly crosslinked. However, both 
TNF-receptor-subtypes are described to be expressed on endothelial cells and associated with 
the activation of NF-κB (1). Although the discovery of the different TNF-receptor subtypes 
dates back to year 1984, for a long time most of TNFα’s effects were attributed to signaling 
trough TNF-R1 as this receptor was better characterized and known to be expressed in most 
tissues and cell types. As it is not ubiquitously expressed, the role of TNF-R2 is less 
described, if not to say underestimated. The receptor specific signaling in the recent years has 
moved more and more into the focus of interest, not only because of intensive investigations 
in the context of the meanwhile widely used TNFα-inhibitors. The treatment of inflammatory 
disorders led to a more extensive focus on the TNF-receptor subtypes, even suggesting 
specific signaling through the different subtypes being responsible for the failing of the 
therapy in certain occasions. TNFα-blockade in more than one clinical study in heart failure 
could not show the expected improvements (92,127) and indeed a recent study by Hamid et 
al. highlighted opposite effects upon activation of TNF-R1 and TNF-R2 in the setting of 
induced heart failure in mice (22). In recent years TNF-R2 has achieved more attention as 
probably playing the crucial role in TNFα induced progression of atherosclerosis (128-130). 
Considering these findings it is of great interest to find out which one of the two main  
TNF-receptor subtypes would be responsible for the prothrombotic effects observed in this 
study. To address this very interesting issue arterial thrombus formation and platelet-
endothelium-interaction was compared in TNF-R1 KO mice, in TNF-R2 KO mice and in 
animals lacking both of the two TNF-receptor subtypes. In these animals also platelet 
aggregation was analyzed. 
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5.5.1 TNF-receptor subtype expression on endothelial cells 
To investigate receptor specific effects of TNFα it is fundamental to know, whether they are 
expressed in the observed cells. As many parameters were influenced by TNFα in endothelial 
cells, within this work it was analyzed whether and if so what TNF-receptors the used cells 
are carrying. Qualitative analysis of TNF-receptor subtypes in whole cell lysates clearly 
proves both the 55 kDa TNF-R1 and the 75kDa TNF-R2 are present on cultured endothelial 
cells in a considerable amount. Characteristic bands could be observed in our endothelial cell 
line (HMEC) as well as the primary cells (HUVEC). As we know TNFα can activate both 
receptor-subtypes we assume that the outcomes observed are the result from signaling through 
both receptor subtypes, TNF-R1 as well as TNF-R2. 
However, one must also be very careful transmitting the information from the 
immunoblotting to the in vivo experiments. To assure that the TNF-receptor subtypes are 
really expressed in endothelial cells of the murine microcirculation immunohistochemnistry is 
required and to obtain information about the localization of the receptors within the cell 
immunofluorescence imaging studies are needed. As specific gene knockdown of a single 
receptor would be the necessary next step in the investigation of receptor specific effects of 
TNFα the information from the blotting will be essential to prove effectiveness of knockdown 
techniques. Some of the mentioned experiments to further clarify the localization of  
TNF-receptors are in progress, but unfortunately not yet included in this work. Nevertheless, 
it can be said that in general both TNF-receptor subtypes are expressed in endothelial cells. 
 
 
5.5.2 TNF-receptor expression in TNF-receptor deficient mice 
To analyze receptor specific effects in vivo C57-BL/6 mice deficient for either one of the two 
TNF-receptor subtypes or both receptors were used. To exclude significant overexpression of 
the respective non knocked-out receptor the expression on the neutrophils of these animals 
were quantitatively analyzed. Neutrophils were used as they are cells of the immune system 
and best described to express both receptor subtypes (8,9). No difference was seen in the 
amount of the non knocked-out receptor in TNF-receptor deficient mice compared to wildtype 
controls, thus concluding there is no compensation in terms of the expression of the other 
receptor. Additionally, this confirms the functional knock-down of these receptors in the 
TNF-receptor deficient animals. 
 
 
5.5.3 Arterial thrombosis and platelet-endothelium-interaction in TNF-receptor deficient 
mice 
Upon the observations that TNFα enhances arterial thrombosis in vivo, the very same 
experiments were performed in mice lacking one or both of the TNF-receptor subtypes. 
Arterial thrombus formation, which was already significantly accelerated in wildtype mice 
receiving TNFα 4 hours prior to the experiment, was even more increased in mice deficient 
for TNF-R1 and could not be seen in mice lacking TNF-R2 only or both TNF-receptor 
subtypes. These observations indicate that TNF-R2 is required to mediate the prothrombotic 
effects of TNFα in vivo, as TNFα was not able to enhance thrombus formation, when TNF-R2 
is missing as it is the case in TNF-R2- or TNF-R1-R2- double-knockout mice. The fact, that 
the prothrombotic effect of TNFα is less pronounced in wildtype mice, where signaling 
through both receptor subtypes is possible, leads to the suggestion that TNF-R1 may exert 
antithrombotic effects or at least may have a compensatory function. However, mice lacking 
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TNF-R2, meaning only TNF-R1 activation is possible, do not show a vessel occlusion time 
which is significantly longer than in mice either not treated with TNFα or lacking both 
receptor subtypes. Therefore, activation of TNF-R1 does not seem to have antithrombotic 
activity itself, but can attenuate the apparent prothrombotic effects exerted upon activation of 
TNF-R2. 
Not only arterial thrombus formation after injury but also the amount of rolling platelets, 
which was not significantly changed by TNFα stimulation in wildtype mice, was increased in 
TNF-R1 KO mice. P-selectin is known to be an important mediator of leukocyte and platelet 
rolling and indeed TNFα induced p-selectin surface expression on endothelial cells. 
Interestingly in vivo increased rolling of platelets could not be observed in wildtype mice, 
when both of the TNF-receptor subtypes are expressed on the endothelium. We therefore 
conclude signaling through TNF-R2 is responsible for transient platelet-endothelium-
interaction while TNF-R1 is partly compensating for the effect. 
 
 
5.5.4 Direct effects of TNFα on TNF-R1 deficient platelets 
As the most striking prothrombotic effects of TNFα in vivo were seen in TNF-R1 deficient 
mice and these animals also showed an increased amount of rolling platelets, platelet 
aggregation was performed in PRP (platelet rich plasma) of TNF-R1 deficient mice. Similar 
as in human platelets and in PRP from wildtype mice no direct influence of TNFα on platelets 
obtained from TNF-R1 deficient mice could be observed. These data further confirmed the 
assumption that the prothrombotic effects of TNFα were due to endothelial activation and not 
due to a direct effect on platelets. Regarding the observation of TNF-R2 mediating 
prothrombotic effects while TNF-R1 being the counterregulating player, these effects are due 
to receptor specific signaling on endothelial cells but not on platelets. 
 
 
The results of this study show that signaling through the different TNF-receptor subtypes 
differentially contributes to the prothrombotic effects of TNFα. In fact it seems like even 
opposite effects are mediated through the receptors. While TNF-R2 is the prothrombotic 
player in this game, TNF-R1 rather represents the antithrombotic counterpart. The results go 
along with observations in other studies where TNF-receptor subtypes upon activation with 
TNFα do not activate the same downstream signaling pathways and do not result in the same 
effects (22). TNF-R2 has been described to be crucial for TNFα induced atherosclerotic 
lesions in mouse models for atherosclerosis (129). Since it has been shown that platelets play 
an important role in the pathophysiology of atherosclerosis (51-56,58), the findings in this 
work that TNFα mediates platelet activation and enhances platelet-endothelium-interaction 
via signaling through endothelial TNF-R2 could be an explanation. Another study could show 
an important role for TNF-R2 in TNFα induced leukocyte rolling and proposed upregulation 
of e-selectin, vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion 
molecule 1 (ICAM-1) as possible mechanisms (21). There are several similarities in terms of 
involvement of cell adhesion molecules between leukocyte and platelet rolling on the 
endothelium (74). So the present data strongly support a role for TNF-R2 in mediating rolling 
of either platelets or leukocytes on the endothelium. For how TNF-R1 is counterregulating 
TNFα’s prothrombotic effects in vivo so far it can only be speculated. However, it can be 
excluded that results are due to over- or underexpression of the receptor subtypes in the 
knockout animals. The downstream signaling pathways of the two TNF-receptor subtypes are 
very complex and partly crosslinked (6,7,9). Further studies are needed to find out how the 
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pathways interact with one another and are able to modulate the effects in the context of the 
prothrombotic actions of TNFα. 
In summary, it can be said that TNF-R2 is required for thrombotic or platelet activating 
effects of TNFα in vivo, while signaling through TNF-R1 may exert compensatory i.e. 
antithrombotic effects. 
 
 
 
 
5.6 Pathophysiological and clinical consequences 
Inflammation plays a crucial role in the pathophysiology of cardiovascular diseases (32). 
TNFα is one of the best characterized inflammatory cytokines and together with its receptor 
system it is essential in many inflammatory processes (26). In this study the influence of 
TNFα and its receptors TNF-R1 and TNF-R2 on arterial thrombus formation and platelet 
activation in vivo was investigated. Arterial thrombosis is the final step in myocardial 
infarction or stroke, mostly on the basis of atherosclerotic plaques. In the last years activated 
platelets and their transient interaction with the endothelium have turned out to play a 
considerable role in the development of atherosclerotic lesions (51-58). 
In our study TNFα promotes arterial thrombus formation and transient platelet endothelium 
interaction in vivo. These effects are mediated by the endothelial TNF-receptor subtype 2 
while TNF-receptor subtype 1 can at least partly compensate for the effects. Hereby these data 
strongly support clinical observations describing chronic inflammatory disorders with 
elevated levels of TNFα going along with increased risk for atherothrombotic events (78-82). 
Even if several effects of TNFα shown in the past were suggestive for prothrombotic effects 
in vivo in this work accelerated thrombus formation upon TNFα stimulation is shown for the 
first time in an in vivo model of arterial thrombosis. Regarding the mechanism there is high 
evidence that our observations are endothelium-mediated and not due to direct activation of 
platelets. Finally by these findings this study contributes to a better understanding of the very 
complex distinctive signaling through the two TNF-receptor subtypes. While acceleration of 
thrombotic vessel occlusion by TNFα was apparent also in wildtype mice but much more 
striking in TNF-R1 deficient animals, increased transient platelet-endothelium-interaction 
also referred to as rolling was only seen in these animals. These observations may illustrate 
why a successful therapeutic approach must be very sophisticated and might explain why 
anticytokine therapy failed to treat cardiovascular diseases in the past. Indeed in the literature 
several clinical studies of “anti-TNFα therapy” for cardiovascular diseases are described 
(92,127). While monoclonal antibodies against inflammatory cytokines as TNFα or IL-1 are 
very successful in the treatment of certain disorders as rheumatoid arthritis or chronic 
inflammatory bowel diseases (24,25,71), these drugs clearly failed to help people with 
chronic heart failure and even led to premature termination of such clinical studies. 
Considering the fact that TNFα acts very specific and can exert even opposite effects by 
activating the two receptor subtypes, we can speculate that the use of TNFα-antibodies could 
also dismantle beneficial effects or at least anticipate compensatory mechanisms mediated by 
one of the receptors. Indeed, in terms of prevention of thrombotic events, also clinical data 
from studies in patients with rheumatoid arthritis receiving anticytokine therapy including the 
TNFα-antibodies Infliximab and Adalimumab as well as the soluble TNF-receptor Etanercept 
remain confusing, since both increased as well as decreased risks for thrombotic 
complications and thromboembolic events have been reported (83,84). However, in the 
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development and progression of atherosclerosis, TNF-R2 seems to mediate the unwanted 
effects while TNF-R1 being rather protective. We should not be discouraged by initial failing 
of anti-inflammatory therapy in cardiovascular disease, but try to further elucidate and clarify 
pathological mechanisms. Since aside from facilitating thrombotic events the  
TNFα-TNF-receptor-signaling plays a role in the development of atherosclerotic lesions, 
specific modulation of TNF-receptors could in general be a therapeutic target. 
Anticytokine therapy to prevent atherothrombotic events will be challenging, not only 
because of distinctive TNF-receptor subtype specific signaling but also because of 
economical reasons, i.e. the extremely high expenses in a health system, which is forced to 
save costs. In any case, for selective receptor targeted therapy the complex signaling of TNFα 
certainly needs to be better understood. However, the current findings suggest that a specific 
blockade of TNF-R2 rather than TNF-R1 may be of potential therapeutic benefit in 
atherothrombotic diseases. 
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6 SUMMARY 
 
Cardiovascular diseases are still the number one cause of death in the western civilization. 
Arterial thrombosis as it happens in myocardial infarction or ischemic stroke is intimately 
linked with inflammation. Elevated serum levels of proinflammatory cytokines correlate with 
an increased risk for atherothrombotic diseases. Several effects of TNFα, the best described 
inflammatory cytokine, on endothelial cells could result in prothrombotic in vivo properties. 
However, it was unclear so far, how TNFα influences arterial thrombosis in vivo, since short 
term but reversible antithrombotic effects have been described. Moreover it was not known, 
what role the two TNF-receptor subtypes TNF-R1 and TNF-R2 play in this context. 
 
In this study the dorsal skinfold chamber was used as an in vivo mouse model to investigate 
arterial thrombosis and platelet-endothelium-interaction. Rolling and firm adhesion of 
fluorescently labeled platelets on the intact endothelium were analyzed by intravital 
microscopy and arterial thrombosis was assessed by measuring the time to thrombotic vessel 
occlusion upon exogenous vessel injury by ferric chloride superfusion. 
In wildtype mice systemic stimulation with TNFα led to a significant acceleration of complete 
thrombotic vessel occlusion after injury. Transient platelet-interaction with the endothelium 
was slightly increased after treating mice with TNFα, but there was no significant increase in 
the amount of rolling platelets, that were defined as the platelets with a velocity of less than 
5% of the maximal platelet velocity. 
To find out, whether the underlying mechanisms for the observed prothrombotic effects of 
TNFα were mediated through a direct effect on platelets or rather through indirect 
endothelium-mediated mechanisms, several in vitro effects of TNFα on platelets and cultured 
endothelial cells were investigated. 
In primary human endothelial cells (HUVEC) a significant increase of O2·− release was 
measured by cytochrome C reduction after stimulation of the cells with TNFα. In the same 
cells TNFα also led to a translocation of the p65-subunit of the transcription factor NF-κB to 
the nucleus, as assessed by immunofluorescence imaging. By FACS analysis the surface 
membrane expression of the adhesion molecule p-selectin was measured, which plays a role 
in platelet-endothelium-interaction and a significant upregulation could be observed after 
stimulating endothelial cells (HMEC) for 4 hours with TNFα. Moreover parameters non 
related to the primary hemostasis were investigated. Tissue factor on the surface of HMEC 
was assessed and quantified by flow cytometric analysis and was markedly increased, when 
cells were treated with TNFα for 4 hours. A similar effect could be observed for PAI-1, where 
significantly elevated mRNA levels assessed by RT-PCR were shown upon stimulation of 
HMEC with TNFα. 
To exclude potential direct effects of TNFα on platelets ex vivo platelet aggregation studies 
using several agonists were performed in human and murine platelet rich plasma (PRP). 
TNFα stimulation of platelets in PRP did neither cause spontaneous aggregation, nor led to 
changes in ADP-, collagen- or TRAP-induced aggregation. 
To find out, which TNF-receptor subtype was responsible for the observed prothrombotic 
effects, arterial thrombus formation and platelet-vessel wall-interaction were studied in vivo in 
TNF-R1-/-, TNF-R2-/- and TNF-R1-/-R2-/- mice. Time to thrombotic vessel occlusion, which 
was already decreased in wildtype mice after TNFα stimulation, was again accelerated in 
TNF-R1-/- animals. Compared to wildtype animals in TNF-R1-/- mice, TNFα also led to 
increased transient platelet interaction with the endothelium, resulting in a greater amount of 
rolling platelets. These effects could not be observed in TNF-R2-/- and in TNF-R1-/-2-/- 
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animals. As TNFα did not enhance platelet aggregation in PRP of TNF-R1-/- mice, these 
results suggest that the endothelial TNF-R2 mediates prothrombotic effects of TNFα. 
 
Taken together, in this study, for the first time prothrombotic effects of the inflammatory 
cytokine TNFα are described using an in vivo model of arterial thrombosis. The data suggest 
that endothelium mediated mechanisms underlie these observations. The mechanisms involve 
an enhanced production of O2·−, activation of NF-κB and expression of the adhesion molecule 
p-selectin on endothelial cells, as well as mechanisms not directly related to the primary 
hemostasis, such as increased tissue factor expression on endothelial cells and mRNA levels 
of PAI-1. The endothelial TNF-receptor subtype 2 was required for prothrombotic effects in 
vivo, while the TNF-receptor subtype 1 partly compensated for these effects. 
 
These data lead to a better understanding of the role of TNFα and its receptors in the 
pathophysiology of atherothrombotic diseases. For the treatment and prevention of such 
diseases by selective receptor targeted anticytokine therapy further studies are needed, but 
nevertheless the findings could contribute to the development of such approaches in the 
future. 
 52 
7 ZUSAMMENFASSUNG 
 
Herz-Kreislauf-Erkrankungen bilden die häufigste Todesursache in den westlichen 
Industrieländern. Entzündliche Prozesse spielen in der Pathophysiologie kardiovaskulärer 
Erkrankungen eine entscheidende Rolle und zahlreiche Studien belegen, dass erhöhte 
Plasmaspiegel von proinflammatorischen Zytokinen wie TNFα das Risiko für 
atherothrombotische Erreignisse wie Myokardinfarkt und Schlaganfall erhöhen. Verschiedene 
in der Literatur beschriebene Effekte von TNFα auf Endothelzellen könnten eine 
prothrombotische Wirkung begünstigen. Es war bisher jedoch noch nicht geklärt, wie TNFα 
arterielle Thrombose in vivo beeinflusst, da nach kurzzeitiger Stimulation auch reversible 
antithrombotische Effekte beschrieben wurden. Weiterhin ist nicht bekannt, welche Rolle die 
beiden TNF-Rezeptor Subtypen TNF-R1 und TNF-R2 in diesem Zusammenhang spielen. 
 
In dieser Studie wurde das Rückenhautkammermodell in der Maus als in vivo Modell zur 
Untersuchung von arterieller Thrombose und Thrombozyten-Endothel-Interaktion verwendet. 
Dabei wurden intravitalmikroskopisch Rollen und feste Adhäsion von Fluoreszenz-markierten 
Thrombozyten mit dem Endothel analysiert und arterielle Thrombose durch Messung der Zeit 
bis zum thrombotischen Gefäßverschluss nach exogener Gefäßverletzung durch Eisenchlorid-
Superfusion untersucht. 
In Wildtyp Mäusen führte die Stimulation mit TNFα zu einer signifikanten Beschleunigung 
des vollständigen thrombotischen Verschlusses nach Gefäßverletzung. Die transiente 
Interaktion von Thrombozyten mit dem Endothel war in Mäusen nach vierstündiger 
Stimulation mit TNFα zwar leicht vermehrt, der Anteil der am Endothel rollenden 
Thrombozyten unterschied sich jedoch nicht von dem in unbehandelten Tieren. Als rollende 
Thrombozyten wurden diejenigen mit einer Geschwindigkeit von weniger als 5% der 
maximal gemessenen Thrombozytengeschwindigkeit definiert. 
Um herauszufinden, ob die beobachteten prothrombotischen Effekte Endothel-vermittelt oder 
durch direkte Wirkung auf Thrombozyten bedingt sind, wurden verschiedene Parameter in 
Thrombozyten und kultivierten Endothelzellen nach Stimulation mit TNFα untersucht. In 
primären humanen Endothelzellen (HUVEC) führte TNFα zu einer signifikanten Erhöhung 
der Superoxidproduktion, welche mittels Cytochrom-C Reduktion bestimmt wurde, sowie zur 
Translokation der p65-Untereinheit von NF-κB in den Zellkern, welche mittels 
Immunofluorescenz-Mikroskopie gemessen wurde. Durchflusszytometrisch wurde die 
Expression des für Thrombozyten-Endothel-Interaktion bedeutenden Adhäsionsmoleküls  
p-Selektin an der Oberflächenmembran von Endothelzellen bestimmt, wobei eine signifikante 
Hochregulation vier Stunden nach Behandlung mit TNFα gemessen werden konnte. Zudem 
wurden nicht direkt auf die primäre Hämostase bezogene Parameter untersucht und die 
Expression von Tissue Faktor an der Oberfläche von Endothelzellen bestimmt, welche durch 
TNFα Stimulation signifikant erhöht wurde. Ähnlich waren die mittels RT-PCR gemessenen 
mRNA Spiegel für PAI-1 (Plasminogen activator inhibitor 1) in HMEC vier Stunden nach 
Stimulation mit TNFα signifikant erhöht. 
Um mögliche direkte Effekte von TNFα auf Thrombozyten auszuschließen wurden in vitro 
Thrombozytenaggregationsmessungen in humanem PRP (Plättchen reiches Plasma) nach 
Stimulation mit verschiedenen Agonisten durchgeführt. TNFα führte weder zu spontaner 
Aggregation, noch wurde die ADP-, Collagen- oder TRAP-abhängige Aggregation 
beeinflusst. 
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Um herauszufinden, welcher TNF-Rezeptor Subtyp für die beobachteten prothrombotischen 
Effekte verantwortlich ist, wurden arterielle Thrombose und Thrombozyten-Endothel-
Interaktion in vivo in TNF-R1-/-, TNF-R2-/- und TNF-R1-/-R2-/- Mäusen analysiert. Die 
arterielle Gefäßverschlusszeit, welche bereits in Wildtyp Mäusen durch TNFα Stiumulation 
beschleunigt wurde, war in TNF-R1-/- Mäusen noch kürzer. Im Vergleich zu Wildtyp Tieren 
führte TNFα in TNF-R1-/- Mäusen auch zu einem erhöhten Anteil von rollenden 
Thrombozyten. Diese Effekte konnten in TNF-R2-/- und TNF-R1-/-R2-/- Mäusen nicht 
beobachtet werden. Da TNFα auch die Thrombozytenaggregation im PRP von TNF-R1 
defizienten Mäusen nicht verstärkte, lassen diese Ergebnisse darauf schließen, dass die 
prothrombotischen Effekte von TNFα in vivo über den TNF-R2 Subtyp vermittelt werden. 
 
Zusammenfassend konnten in dieser Studie zum ersten Mal prothrombotische Effekte des 
inflammatorischen Zytokins TNFα in einem in vivo Modell für arterielle Thrombose gezeigt 
werden. Die Ergebnisse weisen darauf hin, dass Endothel vermittelte Mechanismen diesen 
Beobachtungen zugrunde liegen. Zu diesen Mechanismen zählen vermehrte Superoxid 
Produktion, NF-κB Aktivierung und Hochregulierung von Adhäsionsmolekülen an der 
Zellmembran, sowie erhöhte Expression von Tissue Faktor und mRNA von PAI-1. Es konnte 
gezeigt werden, dass der endotheliale TNF-Rezeptor Subtyp 2 für die prothrombotischen 
Effekte in vivo verantwortlich ist und diese durch Signaling über den TNF-Rezeptor Subtyp 1 
teilweise kompensiert werden können. 
 
Diese Erkenntnisse führen zu einem besseren Verständnis der Bedeutung von TNFα und 
seinen Rezeptoren für die Pathophysiologie von artherothrombotischen Erkrankungen. Auch 
wenn für Behandlung oder Prävention dieser Erkrankungen durch gezielte Rezeptor 
spezifische Therapie sicherlich weitere Studien erforderlich sind, könnten die Ergebnisse zur 
Entwicklung solcher Ansätze in Zukunft beitragen. 
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8 APPENDIX 
 
8.1 Non-standard abbreviations and acronyms 
ADP   adenosine diphosphate 
BSA   bovine serum albumin 
CD40L  CD40 ligand 
CD62P  p-selectin 
Da   Dalton 
eNOS   endothelial nitric oxide synthase 
FACS   fluorescence activated cell sorting 
FITC   fluorescein isothiocyanate 
GPIb   glycoprotein Ib 
HMEC  human microvascular endothelial cells 
HUVEC  human umbilical vein endothelial cells 
ICAM-1  intracellular adhesion molecule 1 
IFNγ   interferon gamma 
IL   interleukin 
KO   knock out 
NF-κB   nuclear factor kappa B 
NO   nitric oxide 
PAI-1   plasminogen activator inhibitor 1 
PBS   phosphate buffered saline 
PRP   platelet rich plasma 
PSGL-1  p-selectin glycoprotein ligand 1 
PVWI   platelet-vessel wall-interaction 
RANTES  Regulated upon Activation, Normal T-cell Expressed and Secreted 
RFU   relative fluorescence units 
ROS   reactive oxygen species 
RPE   R-phycoerythrin 
RT-PCR  real time reverse transcriptase polymerase chain reaction 
SOD   superoxide dismutase 
TNF-R1  tumor necrosis factor-receptor subtype 1 
TNF-R1-/-  tumor necrosis factor-receptor subtype 1 – knock-out 
TNF-R1-/-2-/-  tumor necrosis factor-receptor subtype 1 and 2 – double knock-out 
TNF-R2  tumor necrosis factor-receptor subtype 2 
TNF-R2-/-  tumor necrosis factor-receptor subtype 2 – knock-out 
TRAP-6  thrombin receptor activating protein 
VCAM-1  vascular cell adhesion molecule 1 
vWF   von Willebrand factor 
WT   wildtype 
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Pircher J, Koch E, Vielhauer V, Chaudhry D, Sohn H-Y, Mannell H, Pohl U, Krötz F. The 
TNF-receptor-subtype 2 mediates prothrombotic effects in vivo. Manuscript in preparation. 
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Pircher J, Vielhauer V, Mannell H, Sohn HY, Klauss V, Pohl U, Krötz F. The TNFα-
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Gesellschaft für Kardiologie 2010, Mannheim, Germany. 
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H. Mannell, F. Fochler, J. Pircher, T. Räthel, B. Gleich, C. Plank, O. Mykhaylyk, C. 
Dahmani, U. Pohl, F. Krötz. Site directed vascular gene delivery by ultrasonic destruction of 
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